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GENERAL INTRODUCTION 
AND OUTLINE1
The focus of this thesis is on patients with metastatic lung cancer who received a systemic 
treatment prior to the end of their life. This topic is studied from different perspectives and 
with different methodologies. Firstly, we looked into what percentage of metastatic lung 
cancer patients actually receive a systemic treatment prior to the end of life. Secondly, we 
studied the goals patients and their oncologists have when starting a treatment for metastatic 
lung cancer, we evaluated the achievement of these goals and the satisfaction with the 
treatment decision according to the patients, their oncologists and their relatives in hindsight.
Epidemiology of lung cancer
Lung cancer is currently one of the most frequently diagnosed cancers worldwide, accounting 
for about 20% of all cancer-related deaths.1-3 According to the Netherlands Cancer Registry 
(Integraal Kankercentrum Nederland)4, over 13,000 patients are diagnosed with lung cancer 
in the Netherlands every year, with a yearly mortality of over 10,000 patients.5 This disease is 
associated with a high symptom burden, a low quality of life and an average five-year survival 
rate of 19%.6-10 Factors contributing to this poor survival rate are comorbid conditions such as 
heart failure or chronic obstructive pulmonary disease and the fact that lung cancer is often 
diagnosed at an advanced stage.11
Lung cancer is classified into several histological subtypes, with approximately 80% of all lung 
cancer cases classified as non-small cell lung cancer (NSCLC) and 15% classified as small cell 
lung cancer (SCLC). The remaining cases comprises of a heterogeneous group of thoracic 
cancer (e.g. mesothelioma). NSCLC is further classified into adenocarcinoma, squamous cell 
carcinoma or large cell carcinoma.12 The five-year survival rate of patients with NSCLC is 24%, 
while patients diagnosed with SCLC have an even worse survival rate of 6%.10 Roughly half of 
the patients presenting with NSCLC have metastasized disease, also known as stage IV and 
for these patients the five-year survival rate is only 7% for NSCLC and 3% for SCLC.13
Systemic treatment of metastatic lung cancer
Systemic treatment is the use of medication to destroy cancer cells. This type of medication is 
given through the bloodstream to reach cancer cells throughout the body.14 According to the 
guidelines from the European Society for Medical Oncology (ESMO), systemic therapy should 
be offered to all metastatic lung cancer patients who have a relatively good performance 
score (ECOG score of 0-2 (Eastern Cooperative Oncology Group)).15 Additionally, every 
treatment strategy should take the following factors into account: histology and molecular 
pathology of the tumour, patient’s age and comorbidities and the patient’s preferences. In 
1995, chemotherapy was established as a valuable systemic treatment for lung cancer when 
the NSCLC collaborative group published a meta-analysis of all randomized NSCLC clinical 
trials performed between 1982-2001. This data showed that treatment with chemotherapy, 
using mainly cisplatin-based regimens, leads to an absolute survival benefit of 10% at 1 year 
compared to best supportive care.16 Later studies showed that the response rate of first 
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line chemotherapy is around 30% with a median duration of response between 3.5 and 5.5 
months.17 Unfortunately, the disadvantages of chemotherapy treatment are the well-known 
adverse events like vomiting, nausea, myelosuppression and alopecia, which vary in severity 
depending on the different chemotherapy regimens and the individual patient characteristics 
such as age and comorbidities.18-20
In the past decade, research on molecular targeted therapy has led to significant clinical 
improvements in various subsets of patients with NSCLC. In particular, Tyrosine Kinase 
Inhibitors (TKIs) act against specific targets, as opposed to classical cytotoxic chemotherapeutic 
drugs that damage all proliferating cells in a nonspecific manner. TKIs are small molecules 
that can easily enter cells and inhibit intracellular tyrosine kinase enzymes, deactivating signal 
transduction cascades resulting in the slowing down of tumour growth. For lung cancer, 
clinical practices worldwide use TKIs directed towards Epidermal Growth Factor Receptor 
(EGFR), Anaplastic Lymphoma Kinase (ALK) and mutations in the BRAF gene.21 Patients 
harbouring a certain mutation, which is about 10% of the patients diagnosed with lung 
cancer, respond much better (a response rate of around 70%) and longer (up to 10 months) to 
TKIs than to chemotherapy.22-26 However, TKIs are unfortunately also associated with adverse 
side effects such as skin problems, chronic diarrhea, fatigue and electrolyte imbalances.27-29
Another more recent promising systemic cancer therapy is immunotherapy using Monoclonal 
AntiBodies (MABs), which are large molecules that usually do not enter cells but primarily 
bind to extracellular targets such as cell surface proteins. In the Netherlands, immunotherapy 
treatment has been introduced for second line therapy after chemotherapy use since 2016.30 
Currently, for patients with metastatic NSCLC and a PD-L1 expression above 50%, monotherapy 
with immunotherapy is considered standard first-line treatment. For patients with a PD-L1 
expression below 50% the new standard therapy is a combination of chemotherapy and 
immunotherapy.31-33 In both cases this is only an option when they do not otherwise have 
contraindications to use of immunotherapy (such as severe autoimmune disease or organ 
transplantation) and have a wild type EGFR and ALK.15 On average, 20% of lung cancer patients 
respond to immunotherapy with a prolonged median survival of 9 to 15 months.34 Similar 
to other cancer therapies, there are several side effects associated with immunotherapy, 
including immune related events in different organ systems like the skin, gastro-intestinal 
tract, endocrine system and urinary system.35
Treatment in the context of the end of life
Previous studies have shown that the percentage of metastatic lung cancer patients receiving 
chemotherapy is around 50% at any time in the disease course36, 37 and between 5% and 28% 
worldwide for receiving it in the last month of life, with 11% in the Netherlands.38, 39 Systemic 
treatment at the end of life may result in increased hospital admissions and consequently, 
increased hospital deaths putting additional pressure on the healthcare system.40-45 In many 
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countries, a substantial percentage of cancer patients die in the hospital46, 47, for patients 
with lung cancer specifically it is found that between 28% and 87% died inside the hospital 
worldwide, with 28% in the Netherlands.48
Many studies have addresses indicators for ‘aggressive care’ at the end of life such as receiving 
systemic treatment in the last month of life, hospital admissions, emergency department 
visits and hospital deaths, which are related to poor quality of care.49-52 For metastatic lung 
cancer patients with a poor prognosis, quality of death is an important factor and dying at 
home is considered as a quality indicator.53 It is known that most patients would prefer to die 
at home.44, 54-57 In 2012, the American Society for Clinical Oncology (ASCO) recommended to 
avoid the use of chemotherapy at the end of life to improve patient care.58 In 2017 the ASCO 
guidelines recommend that ‘patients with advanced cancer should receive dedicated palliative 
care service, early in the disease course, concurrent with active treatment’.59
According to the World Health Organization (WHO), ‘palliative care; is: ‘an approach that 
improves the quality of life of patients and their families facing the problem associated 
with life-threatening illness, through the prevention and relief of suffering by means of 
early identification and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual’.60 Several studies have shown that ‘early palliative care’, 
i.e. ‘palliative support alongside standard cancer care shortly after a patient is diagnosed 
with incurable cancer’ may even improve overall survival.61-63 A study of Temel et al. showed 
that among patients with metastatic non-small-cell lung cancer, early palliative care led to 
significant improvements in both quality of life and mood as compared with patients receiving 
standard care. Patients receiving early palliative care had less aggressive care at the end of 
life and even an improved overall survival. Both have their benefits and administering these 
therapies in conjunction could have the greatest benefit.
Treatment decisions and goals for treatment
Once the diagnosis is known, lung cancer patients receive information on the disease from 
their oncologist and a decision has to be made about treatment and care. The emotional 
impact of the diagnosis is huge for patients and therefore the information provided 
regarding the diagnosis, which may be complex, is often difficult for them to understand 
and remember.64-69 For metastatic lung cancer patients, treatment should be aimed at 
life extension and/or improving quality of life without any prospect of curing the cancer. 
However, many patients receiving chemotherapy for incurable cancer do not understand 
that the treatment is unlikely to be curative.70 Furthermore, there is contradictory research 
regarding the effects of chemotherapy treatment: in some studies systemic treatments appear 
to improve patient quality of life71, 72, whereas other studies found no improvement or even 
a decline in quality of life.6-9, 73 Research has shown that severely ill patients will often wish 
for treatment even if the treatment only has small benefits or is ineffective. Certain patients 
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are also willing to tolerate the toxicity for the hope of some life prolongation with quality of 
life as secondary importance.74-76 
In summary, the decision whether to start or continue with a systemic treatment is complex 
and requires careful consideration of patient’s expectations, preferences and values regarding 
the benefits and risks. Not much is known yet about the treatment incentives patients and 
oncologists have when starting a systematic treatment for an incurable disease and how 
well these thoughts are discussed. Since more treatment options have become available, 
treatment decisions in the last phase of life have become a delicate process. In the last few 
decades, patients satisfaction has become an important endpoint in the assessment of the 
quality of care.77 It is of importance and yet not known to what extent certain treatment 
goals are achieved according to patients and oncologists after a systemic treatment and 
how satisfied they are on the choice that had been made to decide for a certain treatment.
The role of oncologists and relatives in treatment decisions for metastatic 
lung cancer
Proper communication by oncologists is crucial for the treatment decision process of 
patients with an incurable disease.78 From literature it is known that oncologists may use 
complicated medical jargon when discussing prognosis and treatment options with a patient 
and sometimes even feel unprepared to have these discussions.79,80 Oncologists may steer 
a patient towards choosing treatment and not properly explain alternatives because they 
want their patients to feel they are being helped and give them some hope, instead of them 
leaving with nothing, which can be perceived as withholding treatment.81-83 Furthermore, 
patients with an incurable disease often have a poor prognostic perception as a result of 
deficiencies in doctor communication and attempts by patients and families to reduce 
the threat of death and maintain hope.84 However, differences are found in the preferred 
level of communication participation between patient populations, for example based on 
age and educational level.85 All these factors play a role in the patient’s decision to start a 
systemic treatment for metastatic lung cancer and the goals and expectations patients have 
for that treatment. Furthermore, oncologists may start a treatment with different goals and 
expectations compared to their patient.86 Direct questions from oncologists on the treatment 
goals may help patients more clearly define their goals and expectations for the treatment 
they wish to receive.87
As mentioned, cancer has a huge emotional impact on the patients but it also has a significant 
emotional impact on the relatives.88, 89 Relatives often accompany patients to a clinical visit 
and help the patients obtain information relevant to medical treatments.90-92 Once treatment 
has been started, patients’ relatives often become the patients’ caregiver and provide them 
with support and care.93 Patients go through the different phases of the treatment together 
13
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with their relatives, thus a relative’s evaluation of the treatment is also important and may 
differ from a patient’s evaluation.
Objectives and research aims of this thesis
The overall aim of this thesis is to gain more insight into the use of systemic treatment for 
metastatic lung cancer patients in the context of the end of life. Research aims are to study:
1. The percentage of metastatic lung cancer patients who receive chemotherapy or TKIs in 
the last month of life in the Netherlands.
2. The percentage of metastatic lung cancer patients who die inside the hospital and whether 
hospital death is associated with receiving systemic treatment in the last month of life.
3. The type and feasibility of treatment goals that patients and their oncologists have when 
starting systemic treatment.
4. To what extent patients’ and oncologists’ treatment goals are achieved after systemic 
treatment and whether this differs between types of therapy. In addition, whether it was 
the right decision to start treatment in hindsight.
5. The perspective of the relatives in hindsight on the achievement of the patients’ treatment 
goals and whether they are satisfied about the patients’ treatment choice.
Methods
The data in this thesis is based upon two studies: a multicentre retrospective patient file 
study in ten hospitals in the Netherlands for the first two research aims (chapter 2 and 3) 
and a multicentre prospective longitudinal questionnaire and interview study on patients, 
oncologists and relatives in six hospitals in the Netherlands for the following three research 
aims (chapter 4 – 6).
The retrospective patient file study was performed in 2016 and 2017. Patients were included 
if they were diagnosed with metastatic lung cancer and died between the 1st of June 2013 
and the 31st of July 2015. A total of 1322 patients were included in this study, ranging from 
70 to 210 patients per hospital. Patient and healthcare characteristics such as age, gender, 
histology of the tumour, type of treatment, date of the last treatment and date of death were 
extracted from the patients’ medical files. 
The multicentre prospective longitudinal questionnaire and interview study was conducted 
between 2016 and 2019. Of the 374 eligible patients who started a systemic treatment for 
metastatic lung cancer, 266 patients and 23 of their prescribing oncologists participated 
(response of 71% and 100% respectively). Before starting a systemic treatment, both patients 
and oncologists received a questionnaire regarding what treatment goals they had and how 
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feasible they perceived these goals to be. After treatment, patients and oncologists were 
asked to what extent these treatment goals were achieved and if they were satisfied with 
the treatment decision made. Additionally, semi-structured interviews with 15 patients and 
5 oncologists were performed to gain additional insight into the mentioned goals, the rate 
of achievement of these goals and the rationale on starting a treatment. 
After the patient died a structured telephone interview was performed with a relative of 
the deceased patient. During the study period, 164 patients were deceased, resulting in 
164 relatives being eligible for participation of which 118 participated in an interview (72% 
response). Relatives were asked to what extent they felt that the patients’ treatment goals 
were achieved and if they were satisfied with the treatment choice made by the patient 
(figure 1).
Outline of this thesis
Chapter 2 presents the percentage of metastatic lung cancer patients who received 
chemotherapy or TKIs in the last month of life in the Netherlands. Chapter 3 reports the 
percentage of metastatic lung cancer patients who died inside the hospital and whether 
hospital death is associated with receiving systemic treatment in the last month of life. Chapter 
4 focusses on the type and feasibility of treatment goals that patients and their oncologists 
have when starting a systemic treatment, the concordance between patients and oncologist 
concerning these goals and how feasible they think these goals are. Chapter 5 describes 
to what extent patients’ and oncologists’ treatment goals are achieved and whether it was 
the right decision to start treatment in hindsight. Chapter 6 elaborates on the perspective 
of the relatives in hindsight on the achievement of patients’ treatment goals and whether 
they are satisfied with the patients’ treatment choice. In the general discussion (chapter 7), 
the main findings from the preceding chapters are discussed. Additionally, methodological 
consideration and implications for practice and future research are formulated.







Figure 1. Graphic representation of the prospective study among patients, oncologists and relatives. 
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Abstract
Objective: Chemotherapy in the last month of life for patients with metastatic lung cancer 
is often considered as aggressive end-of-life care. Targeted therapy with tyrosine kinase 
inhibitors (TKIs) is a relatively new treatment of which not much is known yet about use in 
the last month of life.
Aim: We examined what percentage of patients received chemotherapy or TKIs in the last 
month of life in the Netherlands.
Methods: Patient files were drawn from 10 hospitals across the Netherlands. Patients had 
to meet the following eligibility criteria: metastatic lung cancer; died between 1-6-2013 and 
31-7-2015.
Results: From the included 1322 patients, 39% received no treatment for metastatic lung 
cancer, 52% received chemotherapy and 9% received TKIs. A total of 232 patients (18%) 
received treatment in the last month of life (11% chemotherapy, 7% TKIs). From the patients 
who received chemotherapy, 145 (21%) received this in the last month of life and 79 (11%) 
started this treatment in the last month of life. TKIs were given and started more often in the 
last month of life: from the patients who received TKIs, 87 (72%) received this treatment in 
the last month of life and 15 (12%) started this treatment in the last month of life.
Conclusion: A substantial percentage of patient received and even started chemotherapy or 
TKIs in the last month of life. For chemotherapy this might be seen as aggressive care. TKIs 
are said to have less side effects, do not lead to many hospital visits and due to the rapid 
response, are considered good palliation. However it is not known, yet possible that, when 
patients still receiving treatment until shortly before death, this might influence preparing 




Palliative chemotherapy, immunotherapy and targeted therapy with tyrosine kinase inhibitors 
(TKIs) are possible treatments for patients with metastatic cancer with the aim of relieving 
symptoms, temporary disease control and prolonging survival. However, it is difficult to 
balance the potential clinical benefit and potential harm due to side effects which may lead to 
a decreased quality of life (QOL).1-4 Moreover, timed discontinuation of these treatments may 
be essential for patients to prepare for their death.1 A recent study of Bekelman et al. (2016) 
showed that up to 12.7% of patients who died with cancer received chemotherapy in the last 
30 days of life.5 In 2012, the American Society for Clinical Oncology (ASCO) recommended to 
avoid the use of chemotherapy at the end-of-life to improve patients’ care.6 Mortality within 
one month after the last chemotherapy has been considered as an (negative) indicator of 
the quality of care.7-9
In case of lung cancer, whether chemotherapy near the end of life is appropriate is frequently 
discussed.10 Metastatic lung cancer is an incurable disease associated with a high burden 
of symptoms, poor QOL and an estimated prognosis after the diagnosis of around 1 year.11 
According to national and international guidelines on lung cancer, patients with lung 
cancer can be treated with chemotherapy, immunotherapy (introduced in 2015) or TKIs. 
The availability of new anticancer agents (i.e. TKIs) has prolonged the timeline of medical 
treatment in metastatic cancer patients.12-21 TKIs are oral drugs directed towards specific 
targetable protein driver mutations, such as EGFR and ALK mutations. Multiple clinical 
trials have shown that TKIs cause less side effects compared to chemotherapy and are 
less burdensome in time and traveling for the patient compared to in-hospital treatments. 
Above that, TKIs are associated with a 5-year survival of more than 50%.16-21 Therefore, the 
urgency to discontinue these drugs in the last month of life may be less obvious compared to 
chemotherapy. Moreover, due to the expected fast response of TKIs, starting these drugs in 
patients with a targetable driver mutation might be beneficial to their quality of life, especially 
in patients with a poor performance score.
Studies of Bekelman et al. (2016) and Yang et al. (2013) reported respectively that within 
different countries 5.7% to 27.7% of patients who died with lung cancer were treated with 
palliative chemotherapy in the last month of life.5, 10 Several studies attempt to identify the 
association between different patient characteristics and the use of palliative chemotherapy 
at the end of life. For instance, patients older than 75 years, women, unmarried patients, 
patients with a poor performance score and patients with comorbidities were less likely to 
receive palliative chemotherapy for metastatic lung cancer at the end of life.1, 7, 22, 23 However, 
for TKIs less is known on how many patients who die of metastatic lung cancer were treated 
in the last month of life and which factors are associated with death within one month 
after the last treatment. A study among stage 3 and 4 lung cancer patients that started 
chemotherapy or TKIs as initial treatment showed that of patients who started chemotherapy 
6.1% and of patients who started TKIs 8.6% died within 30 days after starting the initial 
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treatment.24 Although 30 day mortality after initial treatment is not immediately comparable 
to the percentage of deceased patients who received treatment in the last month of life, this 
shows that treatment with TKIs in the last month of life also occurs. 
In light of the above, we studied what percentage of patients with metastatic lung cancer 
receive chemotherapy or TKIs and what percentage of patients receive this in the last month 
of life. We also investigated which characteristics of patients, healthcare and oncologists are 
associated with receiving chemotherapy or TKIs in the last month of life.  
Methods
Study design and population
We have conducted a retrospective patient file study in 10 hospitals across the Netherlands, 
3 academic and 7 non-academic. We extracted demographic and clinical characteristics from 
medical files of patients who died of metastatic lung cancer. Medical files were selected based 
on Diagnosis Treatment Combinations (DBC) codes (DBC 1303 = Non-Small Cell Lung Cancer 
(NSCLC), DBC 1304 = Small Cell Lung Cancer (SCLC)) or International Classification of Diseases 
(ICD) codes, Ninth and Tenth Revision (ICD9 and ICD10 for (N)SCLC). Out of this selection, 
patients were included if they were diagnosed with metastatic lung cancer and died between 
the 1st of June 2013 and the 31st of July 2015. We excluded patients when they were not 
treated for lung cancer in the investigated hospital (n=123), when they were treated with an 
experimental drug for lung cancer (n=6), or when the date of the end of treatment was not 
known (n=18). A total of 1322 patients were included in this study, ranging from 70 till 210 
patients per hospital.
Ethics, consent and permission
This study was approved by the medical ethical committee (METc) of the VU University 
Medical Centre in Amsterdam, the Netherlands. According to the committee, obtaining 
informed consent of the family of the patients was not required since this study is based on 
medical files of patients who already died and data is handled anonymously.
Statistical methods
Statistical analyses were conducted using IBM SPSS statistics 22. Differences between the 
demographic characteristics of the study participants were tested with Analysis Of Variance 
(ANOVA) for the continuous variable age and with the chi-square test for dichotomous and 
nominal variables. A P-value of ≤0.05 denoted statistical significance. Generalized Estimated 
Equation (GEE) was used to attain understanding of the association between patient, 
healthcare and oncologist characteristics and the use of chemotherapy or TKIs in the last 
month of life. By using the 10 hospitals as a subject variable, GEE avoid the cluster effect 
present in the commonly used logistic regression models.
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The dependent variable was the use of chemotherapy or TKIs in the last month of life. This 
variable was dichotomized in: ‘use of medical treatment in the last month of life (yes/no)’. 
The independent variables were patient, healthcare and oncologist characteristics. Patient 
characteristics were sex (male/female), age (≤60, 61-70, ≥71), marital status (married/
unmarried), comorbidity (yes/no), histology of the tumour (SCLC, NSCLC with targetable 
driver mutation (NSCLC+), NSCLC without targetable driver mutation (NSCLC-)) and 
performance status (ECOG (Eastern Cooperative Oncology Group) score 0, 1, 2, ≥3 or not 
known). When the performance status was described using the Karnofsky score, this was 
recoded into the ECOG score (90-100% = 0, 70-80%=1, 50-60% =2, 30-40%=3, 10-20%=4). 
Healthcare characteristics were type of medical treatment for metastatic lung cancer 
(none/chemotherapy/TKIs), started medical treatment in the last month of life (yes/no), 
line of medical treatment (first, second, third and more) and hospital type (academic/non-
academic). Oncologist characteristics were sex (male/female) and age (≤40, 41-50, ≥51). 
Each statistically significant variable in the univariate GEE analyses (p<0.10) was entered into 
a multivariate GEE model. The final model was derived using the backward selection method, 
with a P-value of <0.05 as considered statistically significant. Results of the GEE analyses are 
presented as odds ratios (ORs) and associated 95% confidence intervals (CIs).
Results
Patient characteristics
From the 1322 patients with metastatic lung cancer 509 patients (39%) did not receive 
chemotherapy or TKIs for metastatic lung cancer. The remaining 813 patients received a 
systemic treatment: 692 patients received chemotherapy (52%) and 121 patients received 
TKIs (9%). The three groups (no treatment, chemotherapy and TKIs) show a statistically 
significant difference on all characteristics: patients receiving no treatment had a higher age 
at death (70 ± 10 years) compared to patients receiving chemotherapy or TKIs (65 ± 9 and 
64 ± 10 years respectively). Moreover, a higher prevalence of comorbidity was observed in 
patients receiving no treatment (81%) compared to patients receiving chemotherapy or TKIs 
(72% and 61% respectively). From the patients who received TKIs, 41 patients (34%) did not 
have a targetable driver mutation (NSCLC-). Only 23 patients with a targetable driver mutation 
(NSCLC+) (5%) received no treatment. Chemotherapy was mostly administered to patients 
in the first line (65%) while TKIs were mostly administered in the third line (41%). Lastly, 
compared to patients receiving chemotherapy or TKIs (65% and 51% respectively), patients 
receiving no treatment were found more often in a non-academic hospital (78%) (table 1).
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Percentage of patients receiving chemotherapy or TKIs in the last month 
of life
From all 1322 patients with metastatic lung cancer, 232 patients (18%) received chemotherapy 
or TKIs in the last month of life: 145 patients (11%) received chemotherapy and 87 patients 
(7%) received TKIs in the last month of life (figure 1a). From all the 692 patients who received 
chemotherapy at any time for metastatic lung cancer, 21% received this medical treatment in 
the last month of life (figure 1c). From all the 121 patients who received TKIs at any time for 
Table 1. Demographic characteristics of study participants (n=1322, column %)
Variable No treatment† Chemotherapy TKIs P
N 509 (39) 692 (52) 121 (9)
Age – Years

















































































TKIs: Tyrosine Kinase Inhibitors; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung 
cancer; NSCLC: non-small cell lung cancer; NSCLC+: NSCLC with targetable driver mutation; NS-
CLC-: NSCLC without targetable driver mutation; N.A.: not applicable. †No treatment is defined as 
receiving no chemotherapy or TKIs for metastatic lung cancer. ‡ >5% missing values: marital status 
(14%). Bold values indicate a difference with a P-value of ≤0.05.
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metastatic lung cancer, 72% received this medical treatment in the last month of life (figure 
1b). From the 145 patients who received chemotherapy in the last month of life, 72 patients 
(50%) only received one cycle (data not shown).
We also looked at the time between initiation of the treatment and death: from the 692 
patients who received chemotherapy at any time for metastatic lung cancer, 79 patients (11%) 
died within one month after start of the chemotherapy. From the 121 patients who received 
TKIs at any time for metastatic lung cancer, 15 patients (12%) died within one month after 
start of TKIs. Of these 15 patients, 8 patients had NSCLC+ and 7 patients had NSCLC-. When 
treatment was given in the last month of life, this treatment was started in the last month of 



















Chemotherapy in the last month
Chemotherapy not in the last month
TKIs in the last month




Patients receiving chemotherapy (%) n=692
Treatment in the last month of life
No treatment in the last month of life
72%
28%
Patients receiving TKIs (%)  n=121
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Figure 1. Percentages of patients receiving edical treatment
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Association between the characteristics of the population and receiving 
chemotherapy or TKIs in the last month of life
In the multivariate model, most variables were not associated with receiving chemotherapy 
or TKIs in the last month of life, except for histology of the tumour and type of treatment: 
patients with NSCLC- had a 0.439 lower odds (p=0.003) of receiving chemotherapy or TKIs 
in the last month of life compared to patients with SCLC. Patients receiving TKIs had a 9.503 
higher odds (p<0.001) of receiving this treatment in the last month of life, compared to 
patients receiving chemotherapy (table 2). Therefore we decided to do a separate GEE 
analysis for patients receiving chemotherapy and TKIs. From these patients receiving TKIs in 
the last month of life, 25 patients (29%) had NSCLC- (data not shown).
Association between the characteristics of the population and receiving 
chemotherapy in the last month of life
Histology of the tumour and line of treatment were associated with receiving chemotherapy 
in the last month of life. Patients with NSCLC- had a 0.468 lower odds (p=0.009) of receiving 
chemotherapy in the last month of life compared to patients with SCLC. Patients who received 
third-line chemotherapy had a 2.016 higher odds (p=0.013) of receiving chemotherapy in the 
last month of life compared to patients receiving first-line chemotherapy (table 3).
Association between the characteristics of the population and receiving 
TKIs in the last month of life
Tumour histology, line of treatment and age of the oncologist were associated with receiving 
TKIs in the last month of life. Patients with NSCLC+ had a 2.529 higher odds (p=0.001) of 
receiving TKIs in the last month of life compared to patients with NSCLC-. Patients who 
received TKIs in the last month of life had a 1.723 higher odds (p=0.042) of receiving this 
in the second line than in the first line. From the patients who received TKIs in the second 
line, 15 patients (48%) had NSCLC-. From the patients who received TKIs in the third line, 19 
patients (39%) had NSCLC-. Patients with a prescribing oncologist in the age range of ≤40 
and 41-50 had respectively a 3.238 and 2.841 higher odds (p=0.036; p=0.027) of receiving 
TKIs in the last month of life compared to patients with a prescribing oncologist in the age 
range of ≥ 51 (table 4).
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Table 2. Univariate and multivariate GEE analyses of factors associated with receiving chemotherapy 




medical treatment in 
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2.212 (1.163 – 4.210)*
0.593 (0.390 – 0.92)*
1.0
0.817 (0.284 – 2.350)









1.560 (1.219 – 1.997)*















1.129 (0.701 – 1.819)















8.182 (5.694 – 11.756)*
1.0
9.503 (5.156 – 17.517)**
OR: odds ratio; CI: confidence interval; TKIs: Tyrosine Kinase Inhibitors; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; NSCLC+: NSCLC with targetable driver mutation; NSCLC-: NSCLC 
without targetable driver mutation. * P-value of ≤0.10; ** P-value of ≤0.05
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Table 3. Univariate and multivariate GEE analyses of factors associated with receiving chemotherapy 
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Age category oncologist
≤ 40 (91)
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1.357 (0.605 – 3.042)
1.0
OR: odds ratio; CI: confidence interval; TKIs: Tyrosine Kinase Inhibitors; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; NSCLC+: NSCLC with targetable driver mutation; NSCLC-: NSCLC 
without targetable driver mutation. * P-value of ≤0.10; ** P-value of ≤0.05
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1.374 (0.712 – 2.641)
1.0
OR: odds ratio; CI: confidence interval; TKIs: Tyrosine Kinase Inhibitors; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; NSCLC+: NSCLC with targetable driver mutation; NSCLC-: NSCLC 
without targetable driver mutation. * P-value of ≤0.10; ** P-value of ≤0.05
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Discussion
From the 1322 patients included in this study, 39% received no treatment for metastatic lung 
cancer, 52% received chemotherapy and 9% received TKIs. In total, 18% received treatment 
in the last month of life (11% chemotherapy and 7% TKIs). When treatment was given, TKIs 
were (still) given more often in the last month of life than chemotherapy (72% versus 21%). 
When treatment was (still) given in the last month of life, this treatment was started in the 
last month of life in 54% in case of chemotherapy and in 17% in case of TKIs.
Our study found a percentage of patients receiving chemotherapy in the last month of life that 
falls within the range of rates found for patients with lung cancer in other studies (between 
5.7% and 27.7%).5, 10 The rate of 11% that we found for the Netherlands is somewhat lower 
than the one of 16,4% found by Bekelman et al. (2016).5 This might be due to the difference in 
methods; making use of administrative claims data as they did in that study gives less precise 
information on the exact date a treatment is started or stopped than a patient file study. The 
percentages found in both studies show that the Netherlands are not among the countries 
with the lowest percentages such as Canada (5.9%) or Norway (5.7%).5 
To our knowledge there are no studies with which we can compare our finding of 7% of 
patients who died with metastatic lung cancer that had TKIs in the last month of life. This 
percentage seems low, but this is for a large part due to TKIs not being given so often to this 
patient group (9% TKIs and 52% chemotherapy).
We found that patients who received TKIs had an odds ratio of 9.5 to still receive therapy 
in the last month of life compared to patients receiving chemotherapy. A salient finding is 
that from patients receiving TKIs in their last month, 71% did not have a targetable driver 
mutation. However, these patients did not receive their TKIs in the first line. Knowing the 
rate of success is low in this group, it is debatable whether this should be considered good 
practice.25 This result resonates with findings of Choi et al. that the time between stopping 
TKIs and death is shorter compared to the time between stopping chemotherapy and death: 
being 19 days compared to 35 days respectively.22 Burgers et al. also found a higher odds 
(OR=1.3) of TKIs compared to chemotherapy with regard to 30 day mortality after the start 
of the initial treatment.24 
TKIs are believed to extend survival with less toxicity and a higher quality of life in patients 
with a specific targetable protein driver mutation. If effective, they usually show a rapid 
response which makes it suitable for patients with a poor performance score. Therefore, 
oncologists may be reluctant to stop this medication even when it is close to the end of life. 
Another reason of reluctance to stop might be that a disease flare after TKIs discontinuation 
may occur.26 Although nausea, vomiting, myelosuppression and alopecia generally occur 
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less frequently than with chemotherapy, TKIs are associated with side effects such as skin 
problems, chronic diarrhoea, fatigue and electrolyte imbalances that should not be ignored.27 
The risk of side effects may also increase closer to the end of life due to altered metabolism 
and interaction with other prescribed medication.28 On the other hand, in a study of Shaw 
et al. (2013), patients reported greater reductions in symptoms of lung cancer and greater 
improvement in global quality of life with Crizotinib (a TKI) than with chemotherapy.21 
However, even with a five-year survival of >50%, timely discontinuation of these treatments 
may be essential to patients for a dignified leave of their loved ones and life itself.1 Therefore, 
more research is needed about the consequences of continuation of TKIs shortly before 
death. Only then it is possible to consider whether not giving TKIs shortly before death should 
be a quality indicator for appropriate end-of-life care, as is not giving chemotherapy shortly 
before death.29 Our result, that in 54% of patients who received chemotherapy in the last 
month of their life this treatment also had started in the last month of life, is an indication of 
overtreatment and supports the relevance of this quality indicator and the recommendations 
of ASCO.6 
Patients who received third-line chemotherapy, had higher odds (OR=2.084) of receiving 
chemotherapy in the last month of life compared to patients receiving first-line chemotherapy. 
In this case it might play a role that patients with already a poor performance status were given 
chemotherapy as a final option for maintaining hope and therefore died shortly after the last 
chemotherapy cycle. SCLC patients may have received chemotherapy for attempted symptom 
control, which might explain the lower odds of NSCLC patients receiving chemotherapy. 
Patients with a prescribing oncologist aged ≤50 had a higher odds of receiving TKIs in the 
last month of life compared to patients with a prescribing oncologist aged ≥51. A possible 
explanation might be that younger oncologists are better up to date compared to their older 
colleagues when it comes to TKIs.
The high number of patients analysed in this study (1322) among ten different hospital sites 
makes the results robust and generalizable. Since all patients diagnosed with metastatic 
lung cancer were included in this study, there is no selection bias. However, this study has 
some potential limitations. First, the inevitable limitation of a patient file study is that we 
are not able to discover the rationale of the patient and the oncologist behind starting and 
stopping of chemotherapy or TKIs. Secondly, data on performance status could not always 
be retrieved from medical records due to the absence of documentation. Thirdly, we only 
documented the last treatment line, therefore we do not know what treatments patients 
received in earlier treatment lines.
In conclusion, our study gives indications of overtreatment at the end of life. An indicator 
is that more than half of patients who received chemotherapy in the last month of life also 
started this treatment in the last month of life. Also that the choice of the treatment among 
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others depends on non-patient related factors such as age of the oncologist might be an 
indication of overtreatment. Additionally, a high percentage of patients treated with TKIs 
did not fulfil appropriate criteria for starting this type of treatment, which might indicate 
overtreatment of negative driver mutation patients. Especially when chemotherapy is started 
shortly before death this can be seen as aggressive care. TKIs are said to have less side effects 
and do not lead to many hospital visits. Therefore, it is debatable whether TKIs started shortly 
before death should be considered as aggressive treatment. However, when still receiving 
it until shortly before death, this might influence preparing for death in a negative way. It is 
important to study whether this is the case. Although this study describes the Dutch situation, 
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Abstract
Objective: Metastatic lung cancer is an incurable disease which results in a high burden of 
symptoms, a poor quality of life and an expected prognosis of less than 1 year after diagnosis. 
Treatment shortly before death may result in potential burdensome and inappropriate 
hospital admissions and hospital deaths. Dying at home is, at a population level, considered 
a quality for good end-of-life care.
Aim: We examined what percentage of patients with metastatic lung cancer died inside the 
hospital and if hospital death, or other characteristics of the patient, oncologist or healthcare, 
were associated with treatment in the last month of life.
Methods: This retrospective cohort study evaluated the medical records of 1322 patients 
with metastatic lung cancer who received care at one of 10 hospitals across the Netherlands 
and died between 1-6-2013 and 31-7-2015. Demographic and clinical characteristics were 
obtained from the medical records.
Results: In total, 18% of the patients died during a hospital admission. This percentage was 
higher for patients who received chemotherapy (42%) or targeted therapy with Tyrosine 
Kinase Inhibitors (25%) in the last month of life. Patients younger than 60 years of age, 
patients who received chemotherapy in the last month of life and patients in whom TKIs were 
started in the last month of life were more likely to die inside the hospital. 
Conclusion: In the Netherlands, fewer than one in five patients with metastatic lung cancer 
died in the hospital and in-hospital death was associated with the relatively late use of 
chemotherapy or targeted therapy. Careful selection of patients for disease-modifying therapy 




Metastatic lung cancer is an incurable disease and the leading cause of death from cancer 
worldwide. This disease results in a high burden of symptoms, a poor quality of life and an 
expected prognosis of less than 1 year after diagnosis.1,2 Treatment is focused on relieving 
symptoms, temporary disease control, and prolonging lifespan. According to international 
guidelines on lung cancer palliative chemotherapy, immunotherapy (introduced in 2015) 
and/or targeted therapy with Tyrosine Kinase Inhibitors (TKIs) directed towards specific 
targetable protein driver mutations (such as EGFR and ALK mutations) are treatments of 
choice.3-6 Aggressive treatment shortly before death is increasing over time7 and may result 
in potential burdensome and inappropriate hospital admissions and consequently hospital 
deaths, which could be a threat to good end-of-life care.8-10
In many countries a substantial part of patients with cancer die in hospitals,11,12 whereas most 
patients prefer to die at home.13-17 In a study of Cohen et al. (2017) between 27.5% (New 
Zealand) and 86.5% (Korea) of patients with lung cancer died inside a hospital, with 28% 
of patients in the Netherlands.18 For metastatic lung cancer patients with a poor prognosis, 
quality of death is an important factor and dying at home is considered, at population level, 
as a quality indicator.19 Multiple studies present factors influencing the probability of death at 
home, with anti-cancer treatment in the last phase of life as one of the factors that may hinder 
patients to die at home.20-22 Results from a systematic review about determinants of home 
and nursing-home death indicate that there are no studies available on factors associated 
with hospital deaths specifically for patients with metastatic lung cancer.23,24
Therefore, we conducted a multicentre study in the Netherlands to examine what percentage 
of patients with metastatic lung cancer died inside the hospital, what percentage received 
a treatment for metastatic lung cancer and what percentage received chemotherapy 
or TKIs in the last month of life. We also examined if hospital death is associated with 
receiving treatment in the last month of life and other patients, healthcare and oncologists 
characteristics. 
Methods
Study design and population
We conducted a patient medical file study in 10 hospitals across the Netherlands, 3 academic 
and 7 non-academic hospitals. We gathered demographic and clinical characteristics from 
medical files of patients who died of metastatic lung cancer. Medical files were selected based 
on Diagnosis Treatment Combinations (DBC) codes (DBC 1303 = Non-Small Cell Lung Cancer 
(NSCLC), DBC 1304 = Small Cell Lung Cancer (SCLC)) or International Classification of Diseases 
(ICD) codes, Ninth and Tenth Revision (ICD9 and ICD10 for (N)SCLC). Out of this selection, 
patients were included if they were diagnosed with metastatic lung cancer and died between 
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the 1st of June 2013 and the 31st of July 2015. A two-year time frame was chosen to assure 
a sufficient sample size. We excluded patients who were referred to another hospital for a 
second opinion and therefore might receive a medical treatment elsewhere (n=123), who 
were treated with an experimental drug for lung cancer (n=6), or if the date of the end of 
treatment was not known (n=18). A total of 1322 patients were included in this study, ranging 
from 70 to 200 patients per hospital.
Ethics, consent and permission
This study was approved by the medical ethical committee (METc) of the VU University 
Medical Centre in Amsterdam, the Netherlands. According to the committee, obtaining 
informed consent of the family of the patients was not required since this study is based on 
medical files of patients who already died and data is handled anonymously.
Statistical methods
Statistical analyses were conducted using IBM SPSS statistics 22. Frequencies were used for 
the descriptive statistics in table 1. Generalized Estimated Equation (GEE) was used to attain 
understanding of the association between patient, healthcare and oncologist characteristics 
and the place of death. By using the 10 hospitals as a subject variable, GEE accounts for the 
cluster effect present in the commonly used logistic regression models.
The dependent variable was the place of death. This variable was dichotomized in: ‘died 
in hospital (yes/no)’. The independent variables were patient, healthcare and oncologist 
characteristics. Patient characteristics were sex (male/female), age (≤60, 61-70, ≥71), marital 
status (married/unmarried), comorbidity (yes/no) and histology of the tumour (SCLC, 
NSCLC with targetable driver mutation (NSCLC+), NSCLC without targetable driver mutation 
(NSCLC-)). Healthcare characteristics were type of medical treatment for metastatic lung 
cancer (none/chemotherapy/TKIs), received medical treatment in the last month of life 
(no/yes; chemotherapy/yes; TKIs), started medical treatment in the last month of life (no/
yes; chemotherapy/yes; TKIs), line of medical treatment (first, second, third and more), and 
hospital type (academic/non-academic). Oncologist characteristics were sex (male/female) 
and age (≤40, 41-50, ≥51). Hospital type and oncologists characteristics were included in 
the analyses since policies and treatment preferences may very between academic-, non-
academic hospitals and oncologists characteristics respectively.
Each statistically significant variable in the univariate GEE analyses (p<0.10) was entered into 
a multivariate GEE model. The final model was derived using the backward selection method, 
with a P-value of <0.05 as considered statistically significant. Results of the GEE analyses are 





From the 1322 patients with metastatic lung cancer, 692 patients (52%) received 
chemotherapy, 121 patients (9%) received TKIs and 509 patients (39%) received neither. 
From the patients who did receive chemotherapy or TKIs, 232 patients (18%) received this in 
the last month of life. A total of 79 patients (6%) and 15 patients (1%) started chemotherapy 
or TKIs in the last month of life (table 1).
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SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors.  
*: >5% missing values: marital status (14%); **None is defined as receiving no medical treatment 
for metastatic lung cancer 
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Percentage of patients who died inside the hospital or at any other place
From all 1322 patients with metastatic lung cancer 239 patients (18%) died inside the 
hospital (figure 1a). No difference was found stratified for patients receiving any treatment 
or no treatment (figure 1b). Patients receiving TKIs showed a larger percentage (21%) of 
hospital deaths compared to patients receiving chemotherapy (18%) (not shown). However, 
a difference was seen when patients received any treatment in the last month of life; 36% 
of these patients died inside the hospital (figure 1c). From the 145 patients who received 
chemotherapy in the last month of life, 61 patients (42%) died in the hospital (figure 1d). 
From the 87 patients who received TKIs in the last month of life, 22 patients (25%) died inside 
the hospital (figure 1d).
Association between the characteristics of the population and hospital 
death
Age, treatment in the last month of life and treatment started in the last month of life were 
associated with death inside the hospital. Patients ≤60 years had a 1.233 times higher odds 
(p=0.039) for death inside the hospital compared to patients with an age of ≥71 years. Patients 
who received chemotherapy in the last month of life had a 3.355 times higher odds (p<0.001) 
for death inside the hospital compared to patients who did not received a treatment in the 
last month of life. Patients in whom TKIs were started in the last month of life had a 9.911 
times higher odds (p<0.001) for death inside the hospital compared to patients who did not 
started a treatment in the last month of life (table 2). From these patients in whom TKIs were 
started in the last month of life and died inside the hospital, 1 patient received this treatment 
in the first line, 5 patients in the second line and 4 patients in the third line or more.
Discussion
Our study showed that 18% of patients with metastatic lung cancer died inside the hospital 
which was independent of receiving treatment or not. Furthermore, 42% of patients who 
received chemotherapy and 25% of patients who received TKIs in the last month of life 
died inside the hospital. Patients younger than 60 years of age, patients who received 
chemotherapy in the last month of life and patients in whom TKIs were started in the last 
month of life had a higher odds to die inside the hospital.
In 2008, 28% of lung cancer patients died inside the hospital in the Netherlands.18 This is a 
higher percentage compared to the results of our study where we show that in 2013-2015 
18% of patients with metastatic lung cancer died inside the hospital. This decrease in hospital 
deaths in 5 to 8 years’ time may be explained by the increased awareness of palliative care 
in general and the developments in home care.
48
Chapter 3

















    
 
 Died inside the hospital     Died at any other place    
18%
82%
Patients receiving any treatment for 
metastatic lung cancer n=813 
17%
83%
Patients receiving no treatment for metastatic 
lung cancer n=509 
42%
58%
Patients receiving chemotherapy in the last 
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In total, 18% of patients received a medical treatment for metastatic lung cancer within the 
last month of life and 7% started this treatment in the last month of life. This is comparable 
to the work of Earle et al.7
Our finding that patients receiving chemotherapy in the last month of life have higher odds 
for hospital death confirms findings from earlier studies that receiving chemotherapy in the 
last month of life is associated with a reduced likelihood of home death.6,19,25 In interpreting 
this result it is important to realize that the fact that a high percentage of home deaths is 
considered a quality indicator of care at the end of life and does not mean that all hospital 
deaths should be avoided. On an individual level it is possible that dying in a hospital is an 
informed decision. Although most patients prefer to die at home,16 hospital death may not 
always equal poor quality of death. A recent study showed that family members were satisfied 
with the quality of care patients received when they died inside the hospital. Symptoms were 
well managed overall and their loved ones were treated with kindness and respect.26 There 
are several possible explanations for the relation between treatment in the last month of 
life and hospital death. Potentially the aggressive character of the treatment increases the 
risk of hospitalization for the treatment of side effects.5 Another explanation may be that 
when a patient is treated for lung cancer, the oncologist is still the main care provider and 
the patient has to come to the hospital now and then, making it more natural to go and 
stay in the hospital when problems occur. Patients in whom treatment for lung cancer is not 
started or stopped are referred back to the general practitioner. In an evaluation study from 
England, general practitioners mentioned that when one of their patients was hospitalized, 
they were rarely contacted by the hospital physicians about the patients’ medical situation. 
Palliative care in the home setting becomes more difficult to accomplish in this scenario.27
Previous studies showed that patients with metastatic cancer who were receiving palliative 
chemotherapy and died inside the hospital are more likely to be younger compared to 
patients who did not received chemotherapy.6,28,29 One possible explanation may be that 
oncologists and/or patients do not want ‘to give up’ when patients are relatively younger 
resulting in starting and/or continuing treatment in the last month of life leading to a higher 
chance of hospital deaths. 
To our knowledge, studies showing higher odds ratios of hospital deaths in patients in whom 
TKIs were started in the last month of life have not yet been published. Our dataset does 
contain patients in whom TKIs are started in the last month of life and died inside the hospital. 
However, this is only a small number (n=15). The use of TKIs might have increased over the 
past years due to rapid developments in this field while our data stems from 2013-2015. To 
draw firm conclusions from this outcome, more research is needed. 
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The high number of patients analysed in this study (n=1322) among ten different hospital sites 
makes the generalizability of the results large. By including 3 academic hospitals and 7 non-
academic hospital distributed across the North, East, South and West of the Netherlands, we 
assume that it is a representative sample of the Dutch population with metastatic lung cancer. 
Since all patients diagnosed with metastatic lung cancer were included in this study, selection 
bias is minimised. To our knowledge, this is the first study that shows factors associated 
with hospital death in patients with metastatic lung cancer. At the same time, this study has 
some limitations. First, because of the retrospective study design we are not informed on 
the preferred place of death. Second, we had information on several possible covariates or 
confounders, but it would have been good to have information on more. This is related to the 
limitations of a patient medical file study. For instance, data on performance status could not 
always be retrieved from medical records due to absence of documentation. Patients with 
a poor performance status might have a higher risk to be hospitalized with death inside the 
hospital as a consequence. Other potentially relevant covariates or confounders are among 
others symptom burden, date of diagnosis, ethnicity and socioeconomic circumstances. 
In conclusion, our study shows that a substantial percentage of patients who received 
chemotherapy or TKIs in the last month of life died inside the hospital. Patients in whom TKIs 
were started in the last month of life even had a higher odds ratio of dying inside the hospital 
compared to patients who did not start in the last month of life. While these treatments 
can be started with a palliative intent, a reluctant attitude towards treatment for metastatic 
lung cancer at the end of life might enhance the opportunity for patients to die at home, 
the preferred place of most people.13-17 Although this study describes the Dutch situation, 
the percentages of hospital deaths for patients with metastatic lung cancer are informative 
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Abstract
Objective: Metastatic lung cancer is an incurable disease and can be treated with systemic 
therapy. These treatments might prolong survival and reduce symptoms, but may also cause 
serious side effects.
Aim: We studied the treatment goals of metastasized lung cancer patients and their 
oncologists before starting systemic therapy, concordance between patients’ and oncologists’ 
goals and feasibility of these goals. 
Methods: This research was conducted between November 2016 and April 2018 in one 
academic and five non-academic hospitals across the Netherlands. A total of 266 patients 
with metastatic lung cancer and their prescribing oncologists (n=23) filled out a questionnaire 
about their treatment goals and the estimated feasibility of these goals before treatment was 
started. Additional interviews were conducted with patients and oncologists.  
Results: Patients and oncologists reported ‘quality of life’ (45%;72%), ‘life prolongation’(45%; 
55%), ‘decrease in tumour size’ (39%; 66%) and ‘cure’ (19%; 2%) as treatment goals. 
The interviews showed that the latter appeared to be often as motivation to stay alive. 
Concordances between patients’ and oncologists’ treatment goals were low (ranging from 
24% to 33%). Patients had slightly higher feasibility scores than oncologists (6.8 vs 5.8 on a 
10-point scale). Educational level, age, religious views and performance status of patients 
were associated with treatment goals. 
Conclusion: Patients and oncologists set various goals for the treatment they receive/
prescribe. Low concordance might exist because different goals are set or due to 
misunderstanding by the patient. Clear communication about treatment goals should be 




In the Netherlands, over 13,000 patients are diagnosed with lung cancer every year.1 Early 
symptoms of lung cancer are non-specific and therefore diagnosis is often made when the 
disease is already in an advanced stage.2 Metastatic lung cancer (stage IV lung cancer) is an 
incurable disease and the leading cause of cancer related death worldwide. It often results 
in a high burden of symptoms, a poor quality of life and an expected prognosis of less than 
1 year after diagnosis.3 4
Chemotherapy, targeted therapy with Tyrosine Kinase Inhibitors (TKIs), and immunotherapy 
are possible treatments for patients with metastatic lung cancer with the aim of relieving 
symptoms, temporary disease control, maintaining or improving quality of life (QOL) and 
prolonging survival. 5-9 These treatments have various side effects and different overall survival 
rates varying from a few months in patients without a treatable driver mutation who do not 
respond to chemotherapy or immunotherapy to a few years in patients with a treatable 
driver mutation.10, 11
Earlier studies showed that patients are willing to undergo treatments that have limited 
benefits with major toxicity.12 Furthermore, it is found that many patients mistakenly believe 
that their metastasized cancers are curable 13-16, or think that the goal/aim of the therapy 
they receive is cure. 15, 17, 18
A few studies looked into patients’ own treatment goals for starting a treatment for metastatic 
cancer. 19-21 Based on a pre-determined list of goals, Nipp et al. and El-Jawahri et al. found that 
‘extend my life as long as possible’ (40% and 30%) and ‘cure my cancer’ (33% and 52%) were 
most often mentioned goals by patients with advanced lung cancer19 and advanced gastro 
intestinal cancer.19, 20 Rand et al. found similar results based on an open ended question about 
goals (‘fight cancer’ 52%, ‘cure’ 40%, ‘live longer’ 32%) for patients with advanced lung or 
gastro intestinal cancer and patients with melanoma.21 In this study they also asked about 
feasibility of goals and found that 66% of the patients thought that ‘cure’ was feasible and 
85% thought that ‘fight cancer’ was feasible.21
We conducted a similar study into patients’ treatment goals, and because our study is more 
recent, we were able to not only include patients receiving chemotherapy, but also include 
patients receiving more currently available immunotherapy and TKIs. The goals possibly differ 
between different treatment therapies. To our knowledge, no previous research has been 
undertaken that compared goals of treatment among oncologists to that of patients with 
metastasized lung cancer. Therefore, we additionally also asked the treating oncologists of 
included patients about their own treatment goals for their patients and compared patients’ 
and oncologists’ goals. 
Our main objectives were to study (1) the treatment goals of both the metastasized lung 
cancer patients and their oncologists before the start of treatment, (2) the concordance 
between patients’ and their oncologists’ goals for the treatment, (3) feasibility of these 
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goals as regarded by the patients and their oncologists and (4) which patient and healthcare 
characteristics are associated with having certain treatment goals.
Methods
Study design and population
We conducted a prospective multicentre study in six hospitals across the Netherlands, one 
academic and five non-academic hospitals, between November 2016 and April 2018. We 
included patients diagnosed with metastatic lung cancer who started a systemic treatment 
(chemotherapy, immunotherapy or targeted therapy with tyrosine kinase inhibitors (TKIs)). 
Patients were allowed to participate multiple times for different lines of therapy. Patients 
and their prescribing oncologists filled out a questionnaire about their treatment goals and 
their estimated feasibility of these goals immediately after the treatment plan was decided. 
After analysing the questionnaires, we conducted additional interviews with a subset of 15 
patients and 5 oncologists from the academic hospital to better understand what they wanted 
to achieve with their treatment goals and how they assessed feasibility.
Questionnaire study
Data collection
Patients were identified from clinic schedules by treating oncologists. An information letter 
was given to the patient by the oncology nurse after the oncologist had discussed the medical 
treatment with the patient. Patients were approached at their next scheduled visit; patients 
who agreed to participate completed the informed consent and the questionnaire, gave 
permission to their oncologist to also complete a questionnaire and agreed to have their 
medical records reviewed. The oncologists completed the questionnaires on their treatment 
goals for the patient independently from the patients. The questionnaires had open ended 
questions on the treatment goals and a scale from 0-10 to rate the feasibility of the goals 
(see Figure A, appendix). In this questionnaire, patients also filled out the validated EORTC-
QLQ-C15 quality of life questionnaire.22 Patient and/or treatment characteristics were 
retrieved from the questionnaire (level of education, marital status, religious views), or from 
medical records (age, gender, histology of the tumour, type of medical treatment, line of 
treatment, comorbidity, ECOG performance score (categorized in 0, 1 and 2 or more) and 
treatment limitations).
Data analysis
The open-ended question about treatment goals was coded. From a subset of questionnaires 
from patients (n=150) and oncologists (n=145), the mentioned goals were coded 
independently and subsequently compared by 4 research members (HRWP, BDO, AM, AB). 
Discrepancies were resolved through discussion until 100% agreement was achieved. The 
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remaining 116 questionnaires from patients and 115 from oncologists were coded by one 
researcher (AM) and discussed with the research team.
Statistical analyses were conducted using IBM SPSS statistics 22. Differences between the 
demographic characteristics of the study participants were tested with Analysis Of Variance 
(ANOVA) for the continuous variable age and with the chi-square test for dichotomous and 
nominal variables. Generalized Estimated Equation (GEE) was used to attain understanding 
of the association between patient and healthcare characteristics and the treatment goals. 
By using the oncologists as a subject variable, GEE avoids the cluster effect present in the 
commonly used logistic regression models. The dependent variables were the goals mentioned 
by patients or oncologists. These variable were dichotomized in goal: ‘quality of life’, ‘decrease 
tumour size’, ‘life prolongation’ and ‘cure’ mentioned (yes/no). The independent variables 
were patient and healthcare characteristics. Patient characteristics were age (≤60, 61-70, ≥71), 
sex (male/female), marital status (married/unmarried), educational level (low/middle/high), 
religious views (yes/no), presence of comorbidity (yes/no), histology of the tumour (SCLC, 
NSCLC with targetable driver mutation (NSCLC+), NSCLC without targetable driver mutation 
(NSCLC-)) and performance status (ECOG (Eastern Cooperative Oncology Group) score 0, 1, 
≥2). When the performance status was described using the Karnofsky score, this was recoded 
into the ECOG score (90-100% = 0, 70-80%=1, 50-60% =2, 30-40%=3, 10-20%=4). Healthcare 
characteristics were type of medical treatment for metastatic lung cancer (chemotherapy/
immunotherapy/TKIs), line of medical treatment (first, second, third and more) and hospital 
type (academic/non-academic). Each statistically significant variable in the univariate GEE 
analyses (p<0.10) was entered into a multivariate GEE model. The final model was derived 
using the backward selection method, with a P-value of <0.05 as considered statistically 
significant. Results of the GEE analyses are presented as odds ratios (ORs) and associated 
95% confidence intervals (CIs).
Additional semi-structured qualitative interviews
In order to better understand patients’ and oncologists’ treatment goals and thoughts on 
feasibility, we did additional interviews with patients who received treatment in the academic 
hospital, and their treating oncologists. Patients were recruited using purposive sampling to 
ensure as much variation as possible in treatment goals, perceived feasibility, sex, age and 
type of treatment. A total of 17 patients were invited, 15 patients agreed to participate. 
All 5 oncologists from these patients were interviewed. All participants were contacted by 
telephone, informed by an information letter and gave written informed consent prior to the 
interview. Patients received a gift voucher for their participation. Transcripts were anonymized 
during transcription. Access to the data was limited to five researchers. 
Data was collected from November 2018 until March 2019. All interviews were performed 
by one researcher (HTK). Interviews were held at the participants’ home or at the academic 
hospital using a semi-structured interview guide (see Table A, appendix) and the questionnaire 
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filled out by the respondent. The length of the interviews varied between 40 and 70 minutes 
for patients and between 25 and 35 minutes for oncologists. All interviews were audio 
recorded and transcribed verbatim. Written summaries were sent by mail to participants 
for member check.
We followed the principles of thematic analysis.23 Three transcripts were coded independently 
by three researchers (HRWP, BDO, HTK) using Atlas.ti 7 and thereafter discussed intensively. 
Subsequently, all remaining interviews were coded by HTK and codes were finally grouped 
in themes and discussed with other researchers (HRWP, BDO, AM, AB).
Ethics, consent and permission
This study was approved by the medical ethical committee (METc) of the VU University 
Medical Centre in Amsterdam, the Netherlands (number NL57455.029.16). Both patients 
and oncologists gave written consent to participate in the study and agreed to have the 
patients’ medical records reviewed.
Results
Sample characteristics
In total, 376 eligible patients with metastatic lung cancer were approached for this study. After 
the information letter and questionnaire were given, 266 patients signed informed consent 
and filled out the questionnaire (figure 1). All 23 treating oncologists of the 266 included 
patients were approached, agreed to participate and filled out their questionnaire for a total 
of 260 patients. In total, 110 patients were not included in the study because participating 
was too emotional for them, because they already died before filling out the questionnaire, 
or because they did not return the questionnaire. Patients who were not included were more 
often female, had a performance score of ≥2, started the treatment in the first line and were 
treated in a non-academic hospital (Table B, appendix). From the included 266 patients, 19 
patients participated twice for different lines of therapy. 
Included patients had an average age of 65 years. Patients were starting treatment with 
immunotherapy (47%), chemotherapy (36%) or targeted therapy with TKIs (17%) respectively. 
Most oncologists were male (56%) and younger than 51 years old (79%). Three quarters of 
the patients were included in an academic hospital (75%) (table 1).
Patients’ and oncologists’ goals when starting medical treatment
We categorized the goals patients and oncologists formulated in four main treatment goals: 
‘quality of life’, ‘decreased tumour size’, ‘life prolongation’ and ‘cure’, and we had a small 
category ‘other’. Answers referring to symptom relieve were categorized as ‘quality of life’, 
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and answers referring to fight cancer or stop cancer as ‘decreasing tumour size’. See table C 
in the appendix for all codes and categories.
Patients reported 1,5 treatment goals on average [range: 1-4]. Overall, 45% of patients 
(n=119) reported ‘quality of life’, 45% reported ‘life prolongation’ as a treatment goal, 39% 
reported ‘decrease in tumour size’ (n=103) and 19% reported ‘cure’ (n=50). 




















Figure 1. Flowchart recruitment of pa�ents and oncologists 
266 pa�ents signed informed consent and 
filled out the ques�onnaire (71%)
     110 pa�ents were not included (29%) 
• 33 pa�ents perceived it as too emo�onal
• 32 pa�ents already died or stopped the 
treatment before filling out the ques�onnaire 
• 32 pa�ents did not hand in the ques�onnaire 
• 13 pa�ents reported another reason
23 oncologists signed informed consent and filled 
out the ques�onnaire for 260 pa�ents (98%) 
 
23 oncologists trea�ng these 266 pa�ents 
Oncologists did not fill in the ques�onnaire 
for 6 pa�ents (2%) 
• 2 ques�onnaires were not filled out 
a�er several reminders (1%)
• 4 ques�onnaires were not filled out 
since oncologists moved to another 
hospital (1%)
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Table 1. Demographic characteristics of study participants (n=266)
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TKI: tyrosine kinase inhibitor; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung 
cancer; NSCLC-: NSCLC without targetable driver mutation; NSCLC+: NSCLC with targetable driver 
mutation.
* Denotes missing of; education: 14%, comorbidity: 3%, ECOG performance score: 9%
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Patients who received chemotherapy or immunotherapy most often reported the goal ‘life 
prolongation’ (52% and 40% respectively). Most patients who received TKIs mentioned 
‘quality of life’ (55%) (figure 2A).
Figure 2A. Goals of patients categorized per type of treatment
Oncologists reported 1,9 treatment goals on average for a total of 260 patients [range: 1-4]. 
For participating oncologists, 72% reported ‘quality of life’ (n=186) as a treatment goal, 
66% ‘decrease in tumour size’ (n=171), 55% ‘life prolongation’ (n=142), and 2% ‘cure’ (n=5). 
Oncologists reported ‘quality of life’ most often for each treatment type (68%, 68% and 80%) 
(figure 2B).
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Total (n=260) Chemotherapy (n=94) Immunotherapy (n=122) TKIs (n=44)
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Concordance and discussion of treatment goals
Concordance between patients’ and oncologists’ treatment goals was overall low. Concordance 
was highest for the goal ‘quality of life’ (33%), followed by ‘life prolongation’ (27%) and 
‘decrease in tumour size’ (24%) (figure 2C). A lower performance status was associated with a 
higher concordance between patients’ and oncologists’ goals (OR=2.321;95%CI=1.135-4.744) 
(table D, in appendix). 
Figure 2C. Concordance between patients’ and oncologists’ treatment goals (n=260)
Patients reported that they discussed their treatment goals in 82% of the cases with their 
oncologists and in 88% with their family. Oncologists reported that they discussed their 
treatment goals in 91% of the cases with the patient.
Expected feasibility of treatment goals
Patients reported an average feasibility for their treatment goals (in mean ± SD) of 6.8 ± 1.6 
(figure 3). Since patients reported all their goals with one score on feasibility, we could only 
analyse the feasibility per goal only when one goal was reported (n=134). These patients 
reported an average SD) feasibility of 6.0 ± 1.3 for ‘quality of life’ (n=24), 6.8 ± 1.6 for ‘decrease 
in tumour size’ (n=42), 7.3 ± 1.4 for ‘life prolongation’ (n=41) and 7.0 ± 1.8 for ‘cure’ (n=27) 
(Figure A, appendix).
Oncologists reported a lower average feasibility for their treatment goals of 5.8 ± 2.1 (mean 
± SD) (figure 3). Their mean feasibility scores (shown in mean ± SD) were 6.1 ± 2.0 for 
‘quality of life’ (n=186), 5.5 ± 2.1 for ‘decrease in tumour size’ (n=171), 5.7 ± 2.2 for ‘life 
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Patient and care characteristics associated with treatment goals
For patient goals, the goal ‘quality of life’ was associated with patients being older, having 
a high educational level and having a lower performance status. The goal ‘life prolongation’ 
was associated with patients being married and patients without religious views. ‘Life 
prolongation’ was mentioned significantly less often by patients who started immunotherapy 
or TKIs, compared to patients who started chemotherapy. The goal ‘decrease in tumour size’ 
was associated with patients being younger and patients having a higher educational level. 
The goal ‘cure’ was associated with patients having a lower educational level and patients 
with religious views (Table 2). 
Oncologists reported the goal ‘quality of life’ less often when patients had a middle educational 
level compared to patients with a low educational level. The goal ‘life prolongation’ was 
reported more often by oncologists for patients having a higher educational level. The goal 
‘decrease in tumour size’ was more often reported by oncologists when patients had no 
religious views and when patients were diagnosed with NSCLC, without or with a targetable 
driver mutation (Table 2).
Further insight in treatments goals and feasibility scores
Setting goals like ‘cure’ or ‘life prolongation’ was mentioned by several patients in the 
additional interviews as an expression of willpower to stay alive and non-acceptance of dying. 
Besides this, goals often were given in order to seize chances for improvement and to actively 
‘fight the fight’ as best as they could, ‘doing everything’ or ‘doing something’ (Table 3, Q1). 
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Table 3. Quotes of patients and oncologists on reasons for setting treatment goals and feasibility scores
No Quotes of patients 
Q1 “And not only [not giving up] for yourself, but also for the people surrounding you. But 
resign yourself, that doesn’t help anyone. No treatment feels like giving up, like, what do 
I care. Yes, you try everything to… You see, if it didn’t work, I wouldn’t be so lucky but at 
least I tried. It is all about doing something.” (P26, female, age 72, talking about treatment 
goal ‘the best quality of life’)
Q2 “And I can try to cure. There is a chance. There will always be a chance. And I try to take 
that chance. I grab all chances I get. I grab everything I can. Nothing is out of my league. 
And one person is not the other one. One person will get very sick, the other one will think: 
I won’t get sick. Yes, that is the thing with chemotherapy, some people get really sick.” 
(P134, , female, age 55, talking about treatment goals ‘to stop the cancer’, to stop the 
tumour’, ‘that specialists might learn from this’)
Q3 “Sometimes I feel like, well, I don’t want to be the biggest optimist, but I always think that 
one can be helped, you never know. Today they have nothing for you but maybe tomorrow 
there will be something. And that is what I try to think. It is hope, hope that there might be 
something. You always have to keep hope, otherwise you can better start arranging your 
funeral.” (P168, male, age 59, talking about treatment goals ‘to rather be better’ and ‘to 
prolong life’)
Q4 “You keep in mind that the eternal live, or let’s say, until your ninety’s, that might be unre-
alistic. But at least, maybe one extra year. So one extra year might be a 5 and (to live) until 
your 99th might be a 10. Yes, and then something in between. The [feasibility score] is kind 
of hope. I hope that it is as long as possible.” ( P175, male, age 64, talking about feasibility 
score of 7)
No Quotes of oncologists
Q5 “I: You just mentioned, maybe that this patient might live a bit longer, that the symptoms 
might be delayed, but I don’t see that goal on your questionnaire.
P: No, I indeed mentioned symptom delay and the question is if that is in line. Most of the 
time it goes hand in hand. People get complaints because they have feelings of nausea, 
have fever, they might die from that. But for her it is about symptom delay I think. Living a 
couple of months longer will for her be..” (O4, oncologist, female, talking about treatment 
goals ‘delay symptoms and ‘decrease tumour growth’)
Q6 “There is always a small chance that it might work. If you don’t do anything, you know you 
will die. And if you than say, I want to grab that opportunity, I think you should just do it, 
even though it might not be the right candidate. If it does work, you are on the winning 
hand so to speak. And now (without starting treatment) you might be losing.” (O5, oncolo-
gist, female, talking about treatment goal ‘decrease tumour growth’)
Q7 “I have the experience with patients by whom it also started like this and that it eventually 
goes well. That is the drive, in the end. I have the experience that there are many people 
who feel better with immunotherapy and also live longer for 2 years with a good quality 
of life. Up front it is not always easy to see if that is the person in front of you. So than you 
think, well we can at least try, otherwise they will most certainly die and this treatment is 
not very burdensome. It is an consideration, yes and people really want to get the chance.” 




Also, patients explained they set treatment goals while realizing that the chances for achieving 
them were small. But they wanted to take any chance (Table 3, Q2).
Patients explained that setting positive treatment goals gave them hope for cure, life 
prolongation or decrease of tumour size which made the disease process more bearable. It 
made patients feel better and functioned as a reason to stay optimistic (Table 3, Q3). Patients 
explained the feasibility scores that they attributed to their goals as an expression of the 
hope for good results (Table 3, Q4). This hope was not so much based on known chances on 
success, but more on oncologists’ willingness to start treatment and examples of patients 
who responded well to treatment.
All oncologists mentioned that their treatments were intended as palliative treatments. When 
specifically speaking in terms of palliative treatment, they aimed at symptom relief, a good 
quality of life or preventing future symptoms. Life prolongation could then possibly be a side 
effect (Table 3, Q5). Besides, interviewed oncologists explained that they did not set cure 
as a goal, because this was not realistic; life prolongation and decrease in tumour size were 
the highest achievable goals. Treatment was perceived by oncologists as the only chance to 
achieve life prolongation. They did not want to miss chances for improvement of the patients’ 
situation, despite small chances for treatment success (Table 3, Q6). No treatment or, in 
interviewed oncologists’ words ‘doing nothing’ was therefore not an option. Oncologists 
mentioned that estimating feasibility of treatment goals is often difficult. Examples of 
unexpected successful results of treatment in former patients, was a reason to set relatively 
high feasibility scores (Table 3, Q7).
Discussion
Patients and oncologists reported ‘quality of life’ (45%;72%), ‘life prolongation’ (45%;55%), 
‘decrease in tumour size’ (39%;66%) and ‘cure’ (19%;2%) as treatment goals respectively. 
Patients who received chemotherapy most often reported ‘life prolongation’ as a goal. Most 
patients who received TKIs reported ‘quality of life’ as a goal. Oncologists reported ‘quality of 
life’ most often for every treatment type. Concordances between patients’ and oncologists’ 
treatment were low: highest for ‘quality of life’ (33%), followed by ‘life prolongation’ (27%) 
and ‘decrease in tumour size’ (24%). Patients had slightly higher feasibility scores than 
oncologists (6.8 vs 5.8 on a 10-point scale). More than known success rates, examples of 
patients where it went unexpectedly well and hope seem to influence the goal setting and 
feasibility score. Educational level, age, religious views and performance status of patients 
were associated with certain treatment goals.
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The percentages of patient treatment goals that we found in our study are partly comparable 
with results of Rand et al., who looked at priority goals in patients with advanced lung cancer, 
advanced gastro intestinal cancer and melanoma.21 We found higher percentages for the 
treatment goals ‘life prolongation’ (45% compared to 32% ‘live longer’ as treatment goal 
found by Rand et al.) and ‘quality of life’ (45%, compared to 30% ‘comfort’ as treatment 
goal found by Rand et al.) and lower percentages for the treatment goal ‘decrease tumour 
growth’ (including fight cancer) (39%), compared to 52% ‘fight cancer’ as treatment goal 
found by Rand et al.21 There is the greatest difference in percentage of patients having ‘cure’ as 
treatment goal (19% in our study compared to 40% in the study of Rand et al.).21 Our findings 
are less comparable with results of Nipp et al. and El-Jawahri et al., who asked patients with 
advanced lung cancer and advanced gastro intestinal cancer for (only) one treatment goal 
(out of a list of possible treatment goals). They found ‘cure’ (33% and 52%), ‘extend life as long 
as possible’ (40% and 30) and ‘lessen my suffering’ (quality of life) (4% and 4%) as treatment 
goals respectively.19, 20
The differences found between the studies might be the result of different research methods, 
but it might also be the result of cultural differences. For the Netherlands it has been found 
that physicians and patients are relatively open in communicating prognosis; this might 
explain the relatively low percentages for ‘cure’ as treatment goal that we found.24
We didn’t find studies on the treatment goals oncologists have when starting a treatment 
specifically for metastatic lung cancer.
Cure is the most difficult goal to understand, as all patients were in the advanced stages of 
a disease. From the interviews it appeared that hope can play an important role in setting 
this goal, which suggests that patients do not necessarily see it as a realistic goal. Rand et 
al. concluded that patients hold optimistic expectations for achieving their goals and for 
surviving.21 Setting ‘cure’ as a treatment goal might therefore be a coping strategy for patients 
dealing with an incurable disease. However it can also be that patients misunderstood that 
they could be cured, as found in previous studies. 13-16, 18, 25 We found an association between 
lower educational level and the treatment goal ‘cure’. This might mean that patients with a 
lower educational level more often think their cancer may be cured. This finding highlights 
the importance of clear communication between oncologists and patients.
The questionnaire study showed that – apart from cure of which they know it is not realistic- 
oncologists least often mentioned life-prolongation as goal; over half of oncologists mentioned 
it. Above that the qualitative study showed that the oncologists generally saw this goal more 
as a side effect of goals related to quality of life and treatment of burdensome symptoms. 
This suggests that they foremost have a palliative intent with starting treatment. At the same 
time they seem to describe the option of not giving systemic treatment as giving no treatment 
or doing nothing, while both patients and oncologists feel they do need to do something, 
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probably because of not wanting to be abandoned by the physician or abandon the patient. 
Introducing palliative care as an option to relieve symptoms and achieve the best possible 
quality of life can therefore be beneficial.
Although patients reported that they discussed their treatment goals in 82% of the cases 
with their oncologists and oncologists in 91% of the cases with the patient, we found overall 
low concordances between patients’ and oncologists’ goals: between 24% for ‘decrease in 
tumour growth’ and 37% for ‘quality of life’. A recent study by Almalki et al. found that only 
13.7% of patients had full concordance with their physicians regarding the aspects of their 
treatment plans. However, this study consisted of a heterogeneous cancer population.26 
Douglas et al. showed that 23.3% of patients with advanced cancer and their oncologist had 
strong goal of care agreement for ‘survival’ (8.3%) or ‘quality of life’ (15%).27 In a South-Korean 
study they found that the agreement rates between cancer patients and oncologists was 69% 
for treatment goal.28 Having a low performance status was related to higher concordance. 
Possibly in these cases it is clearer which goals can still be strived for.
The concordance was especially low for the goal ‘decrease tumour size’. The interviews 
with oncologists showed that with their direct goal of decrease tumour size, they wanted 
to achieve a more ultimate goal, for instance delaying symptoms (Q5 in table 3). It is 
possible that an oncologist puts emphasis on the direct goal in the questionnaire and more 
emphasis on the ultimate goals in the discussion with the patient (or vice versa). In such 
cases non-concordance between patients’ and oncologists’ treatment goals might be an 
artefact. Another explanation might be that patients misunderstood what the oncologist 
communicated. Chou et al. concluded that the oncologists’ language may obscure discussions 
of (prognosis and) treatment goals. They observed that oncologists can use complex language, 
medical jargon, modal expressions (indirectness) and euphemisms in their conversations with 
patients with advanced cancer.29 Using ‘decrease tumour size’ instead of what they want to 
achieve with this decrease – increased quality of life or life-prolongation–can be seen as an 
example of this. However, it might also be that patients and oncologists actually had different 
goals, without misunderstanding; in those cases non-concordance is logical. Nevertheless, 
discussing patients’ treatment goals is part of high-quality care, allowing physicians to align 
treatments with what is most important and realistic to the patient.30, 31
Feasibility scores for different goals differed for patients and oncologists, with patients giving 
slightly higher scores. From the interviews it appeared that most patients mentioned ‘hope’ 
as an explanation for a high feasibility score before treatment. This might also explain the 
rather high feasibility score of 7,0 for ‘cure’. It became clear that oncologists can also have an 
influence on this ‘hope’. Their willingness to start a treatment fed patients’ hope for a cure or 
for life prolongation as seen in the interviews. Rand et al. found a similar feasibility score for 
‘cure’ (6,6) and a higher score for ‘fight cancer’ (8,4, compared to 6,8 we found for ‘decrease 
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tumour growth’).21 Oncologists mentioned that it is difficult to determine feasibility scores, 
but that they took into account the chance that the treatment could be beneficial or could 
have unexpected results.
Strengths and limitations
Strengths of this study are the large sample size of patients, the contribution of both one 
academic and five non-academic hospitals, the use of open ended questions, so that patients 
and oncologists had to formulate goals in their own words and the additional semi-structured 
interviews to better understand respondents answers. A limitation is that we only interviewed 
patients and oncologists from the academic hospital, possibly giving bias to the additional 
information since this may be a different kind of patient population wherein more treatment 
lines and new therapies are available and patients might be more willing ‘to try everything’.
Conclusion and implications
Patients and oncologists set various goals for the treatment they receive/prescribe. There 
are no relevant differences in the treatment goals between chemotherapy, immunotherapy 
or targeted therapy. Concordance between patients’ and oncologists’ goals is low. This might 
be because they actually have different goals, but it might also be the result of the patient 
misunderstanding the effectiveness or side effects of treatments. Patient characteristics, such 
as age and educational level can play a role in this, but also suboptimal communication of 
the oncologist. It is important that the oncologist informs patients and their families clearly 
about the feasibility of their treatment goals and help them to make decisions that best suit 
their preferences. As patients can only make a well-considered decision if they are adequately 
informed, clear communication about treatment goals should be integrated into clinical care. 
This communication should include the option of palliative care. Attention for this in education 
and training of oncologists can help with achieving this. Following the principles of shared 
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APPENDIX
Ques�onnaire for pa�ents:  











- “To what extent do you think these goals are feasible?”  
0    1    2    3    4    5    6    7    8    9    10 
not feasible at all                      highly feasible 
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Figure A. Questionnaires for patients and oncologists
 Ques�onnaire for oncologists: 
- “Who made the treatment decision?”  
The pa�ent wanted this treatment 
I decided for this treatment 
The pa�ent and I decided together 
 












- “To what extent do you think these goals are feasible?”  
1.       0    1    2    3    4    5    6    7    8    9    10 
2.       0    1    2    3    4    5    6    7    8    9    10 
3.       0    1    2    3    4    5    6    7    8    9    10 
4.       0    1    2    3    4    5    6    7    8    9    10 
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Figure B. Feasibility of treatment goals according to patients and oncologists. Note: feasibility score of 
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Table B. Comparison of included and not included patients 
N=376
Variable (N)
Patients who were 
included (column %)














































NSCLC without targetable driver 
mutation (258)



































ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; NSCLC: non-small cell lung 
cancer; TKIs: Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value of ≤0.05.
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Table C. Examples of treatment goals from patients and oncologists
Category English
Quality of life Having a more comfortable life
Better quality of life
Better mobility
Feeling better
Being able to do more things than I can do now
The best quality of life
Making the quality of life as high as possible
Having a bearable life
Having a pleasant life
Good quality of life
Quality of life
Improve quality of life
Improve life
Strive for a better life than I have now








Being less ill 




To stop cancer cells from growing
To stop the cancer
To prevent the cancer from growing
To control cancer
That the cancer disappears
To decrease the tumour cells
That the tumour disappears
That it does not grow any further
High stabilization of the disease
To fight the cancer
Prevent new metastases
To stop the tumour from growing
To delay the cancer process
To stop the cancer
Stopping the disease process
To shrink the tumour
To slow down the disease
To slow down the cells
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To withhold the tumour
To shrink the tumour
To delay the growth
Life prolongation Better life opportunities
To live longer



















Other Visiting Suriname 
Nothing
To keep the option for radiation
To quit 
To do everything about it
Improve medication for future patients
To contribute to science 
So that specialists can learn 
To have the feeling I have tried everything 
Gain more insight in research 






















1.199 (0.560 – 2.567)



























0.894 (0.475 – 1.683)


























1.797 (0.777 – 4.159)





NSCLC without targetable driver 
mutation (182)






0.834 (0.417 – 1.667)
1.068 (0.255 – 4.475)
0.607
0.928








0.637 (0.314 – 1.291)











0.875 (0.539 – 1.420)











OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell 
lung cancer; NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors  
*p value ≤ 0.05
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Abstract
Objective: Previous studies have investigated patients’ treatment goals before starting a 
treatment for metastatic lung cancer. Data on the evaluation of treatment goals are lacking.
Aim: To determine if patients with metastatic lung cancer and their oncologists perceive the 
treatment goals they defined at the start of systemic treatment as achieved after treatment 
and if in hindsight they believe it was the right decision to start systemic therapy.
Methods: A prospective multicentre study in six hospitals across the Netherlands between 
2016 and 2018. Following systemic treatment, 146 patients with metastatic lung cancer and 
23 oncologists completed a questionnaire on the achievement of their treatment goals and 
whether they made the right treatment decision. Additional interviews with 15 patients and 
5 oncologists were conducted. 
Results: According to patients and oncologists, treatment goals were achieved in 30% and 
37% for ‘quality of life’, 49% and 41% for ‘life prolongation’, 26% and 44% for ‘decrease in 
tumour size’ and 44% for ‘cure’ respectively. Most patients and oncologists, in hindsight, felt 
they had made the right decision to start treatment, also if they had not achieved their goals 
(72% and 93%). This was related to the feeling that they had to do ‘something’.
Conclusion: Before deciding on treatment, the treatment options, including their benefits 
and side-effects, and the goals patients have, should be discussed. It is key that these 





Lung cancer is the most frequent cause of cancer-related deaths worldwide.1 In the 
Netherlands, over 14,000 patients are diagnosed with lung cancer each year.2 Lung cancer 
is mostly diagnosed in an advanced stage since earlier stage disease may not always cause 
disease specific symptoms.2 At time of presentation, lung cancer frequently has an aggressive 
course of disease, even with systemic treatment.3 
Systemic treatments such as chemotherapy, targeted therapy with tyrosine kinase inhibitors 
(TKIs) and immunotherapy are often initiated in patients with metastasized lung cancer 
despite the aggressive course, the incurability and the possible side effects.4-10 
Previous studies have looked into treatment goals patients have when starting systemic 
treatment for metastatic lung cancer. Goals that were mostly mentioned by patients in these 
studies are ‘quality of life’, ‘life prolongation’, ‘decrease of tumour growth’ and ‘cure’.10-13
Data on the evaluation of treatment goals are lacking. To what extent do patients and 
oncologists perceive their goals as achieved after treatment, and do they, in hindsight, think 
it was the right decision to start systemic therapy? Insight from this evaluation can help 
future patients and oncologists to make the decision about whether or not to start systemic 
treatment. The main objectives of this study were, from the perspective of patients and 
oncologists separately, to determine (1) the percentage that achieved treatment goals as 
defined at the start of treatment, (2) which characteristics of patients and healthcare were 
associated with achievement of treatment goals and (3) whether, in hindsight, it was the 
right decision to start the treatment.
Methods
Study design and population
We conducted a prospective multicentre study in six hospitals (one academic and five 
non-academic) across the Netherlands between November 2016 and April 2018. We 
included patients diagnosed with metastatic lung cancer who started a systemic treatment 
(chemotherapy, immunotherapy or targeted therapy with TKIs) as part of usual care. 
Patients and their oncologists received a questionnaire on their treatment goals after the 
treatment regime was discussed between the patient and their oncologist and before the 
start of systemic treatment. Within two weeks after the agreed upon systemic treatment was 
completed the patients received a questionnaire about the achievement of the treatment 
goals they had defined at the start of treatment and whether, in hindsight, they felt starting 
the treatment had been the right decision. The study team was aware of this moment 
of completion of treatment (this could be within weeks or within months) due to weekly 
multidisciplinary team meetings where treatment of all metastatic lung cancer patients were 
discussed. After analyses, we felt the need to better understand respondent answers, e.g. 
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considering starting the treatment to be the right decision even if stated treatment goals 
were not achieved. Therefore, we conducted additional qualitative interviews with a subset 
of patients and oncologists. For reasons of feasibility we limited these interviews to patients 
of an academic hospital. We considered this possible because we did not find differences in 




Patients completed the informed consent and gave permission for their oncologist to complete 
their questionnaires and to have their medical records reviewed. The patient and oncologist 
completed the questionnaires independently. The pre-treatment questionnaire included an 
open-ended question on their treatment goals. In the post-treatment questionnaire, the 
exact goals provided on the first questionnaire were copied on the second questionnaire. For 
each goal, respondents were asked to what extent it was achieved using a response scale of 
0-10 (see appendix, figure A). In addition, the second questionnaire contained the question: 
In hindsight, do you think it was a right decision to start this treatment? Patients also filled 
out the validated EORTC-QLQ-C15 quality of life questionnaire.14 Patient and/or treatment 
characteristics were retrieved from the questionnaire or medical records.
Data analysis
The goals patients and oncologists described in the open-ended question were coded. From 
a subset of 145 questionnaires filled out by patients and oncologists, the goals listed were 
coded independently and subsequently compared by 4 research team members (HRWP, BDO, 
AM, AB). Discrepancies were resolved through discussion until 100% agreement was achieved. 
The remaining 116 questionnaires from patients and 115 from oncologists were coded by 
one researcher (AM) and discussed with the research team. This resulted in goals being 
categorized into four main groups: ‘quality of life’, ‘decreased tumour size’, ‘life prolongation’ 
and ‘cure’; these groups were used in our analyses.10 See appendix for all goals and categories 
(Table A). We dichotomized the scores by the extent to which the goal was achieved (0-10). 
We used a cut off value of 7 or higher to define goals as achieved, because the qualitative 
interviews showed that patients and oncologists generally regarded goals as achieved if rated 
with at least a 7. We conducted a sensitivity analyses by performing the regression analyses 
with a cut off score of 6 (see appendix table D and E).
Statistical analyses were conducted using IBM SPSS statistics 24. Differences between 
the demographic characteristics were tested with Analysis of Variance (ANOVA) for the 
continuous variable of age and with a chi-square test for dichotomous and nominal variables. 
A Generalized Estimated Equation (GEE) was used to attain understanding of the association 
between patient and healthcare characteristics and the achievement of treatment goals 
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(dependent variable). By using the oncologists as a subject variable (23 oncologists provided 
information on their treatment goals for the included patients), GEE avoids the cluster effect 
present in the commonly used logistic regression models. The individual level of observation 
in this analysis is the treatment goal (and not patient or oncologist) in order to analyse the 
relation between type of treatment goal and achievement of goals. We did not correct for 
clustering on the patient level as there were too few observations (goals) per cluster. Among 
patients, 56% of clusters had 1 observation and 39% of clusters had 2 observations. Among 
oncologists, 26% of clusters had 1 observation and 57% of clusters had 2 observations. The 
independent variables used in the analyses were age, sex, marital status, educational level, 
being religious, presence of comorbidity, histology of the tumour, and performance status 
(ECOG (Eastern Cooperative Oncology Group) score 0, 1, ≥2)), type of systemic treatment for 
metastatic lung cancer, line of systemic treatment and hospital type. Karnofsky scores were 
recoded into an ECOG score (90-100% = 0, 70-80%=1, 50-60% =2, 30-40%=3, 10-20%=4).15 
Each statistically significant variable in the univariate GEE analyses (p<0.10) was entered into a 
multivariable GEE model. The final model was derived using the backward selection method, 
with a P-value of <0.05 considered statistically significant. Results of the GEE regression 
analyses are presented as odds ratios (ORs) and associated 95% confidence intervals (CIs).
Additional semi-structured qualitative interviews
In order to understand the outcomes of patients and oncologists from the questionnaire 
study, additional interviews were conducted with 15 patients (17 were invited, 15 agreed to 
participate) from the academic hospital, and their 5 oncologists. Patients were recruited using 
purposive sampling to ensure as much variation as possible. Criteria that drove the purposive 
sampling were whether participants’ goals were achieved or not achieved, what type of 
treatment goals were mentioned, gender and age. Potential participants were contacted by 
telephone and received an information letter. All participants gave written informed consent 
prior to the interview. Patients received a gift voucher for their participation.
All in-depth interviews were performed by one researcher (HTK) between November 2018 
until March 2019 at the participant’s home or the hospital. Participants were asked to explain 
their answers in the questionnaire using a semi-structured interview guide (see appendix, 
table B). The length of the interviews ranged from 40-70 minutes for patients and 25-35 
minutes for oncologists. All interviews were audio recorded and transcribed verbatim. A 
summary of the interview of about 400 words was sent to the participant to confirm that 
some of the answers were interpreted correctly. However, none of the participants disagreed 
with the interpretations. We followed the principles of thematic analysis.16 Three transcripts 
were coded independently by three researchers (HRWP, BDO, HTK) using Atlas.ti 7 and 
thereafter discussed intensively. Subsequently, all remaining interviews were coded by one 
researcher (HK). Codes were then discussed with other researchers (HRWP, BDO, AM, AB) 
and grouped in themes.
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Ethics, consent and permission
This study was approved by the medical ethical committee (METc) of the VU University 
Medical Centre in Amsterdam, the Netherlands (number NL57455.029.16). Both patients 
and oncologists gave written consent to participate in the study and for patients to have 
their medical records reviewed. Transcripts were anonymized after transcription. Access to 
the data was limited to five researchers.
Results
Sample characteristics
In total, 376 eligible patients with metastatic lung cancer were approached. Of these, 
266 patients and 23 oncologists for 260 patients signed informed consent and filled out 
a questionnaire on their treatment goals before treatment. After systemic treatment, 146 
patients and 23 oncologists for 223 patients completed the second questionnaire (61% and 
95% respectively) (see figure 1). Patients and oncologists reported 1,5 and 1,9 treatment 
goals on average respectively [range: 1-4].
Patients who filled out the questionnaire after treatment (n=146) and patients who had not 
filled out the questionnaire after treatment (because they died during the treatment (n=72) 
or for other reasons (n=22)), were compared on all characteristics. Differences were found 
only for ECOG performance status. (See appendix, table C).
Among the 146 patients, 61 patients had received chemotherapy (42%), 65 patients had 
received immunotherapy (44%) and 20 patients had received TKIs (14%). Demographic 
characteristics of these patients are presented in table 1.
Achievement of defined goals after a systemic treatment according to 
patients and oncologists
All 146 patients scored the extent to which their defined treatment goals (219 in total) were 
achieved. All 23 oncologists did the same for the 428 defined treatment goals they identified 
for 223 patients. Scores ranged from 0 to 10, with a score of 0 being given relatively frequently 
especially among oncologists (figure 2). Using a cut-of-score of 7, patients reported the goals 
‘quality of life’, ‘life prolongation’, ‘decrease in tumour size’ and ‘cure’ as achieved in 30%, 
49%, 26% and 44% respectively. When asked whether their treatment goals had changed 
over the course of treatment, 72% of patients responded there had been no change in goals.
Noted changes were primarily related to lowering expectations due to a worsening condition 
or realizing expectations were too high.
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Oncologists reported the goals ‘quality of life’, ‘life prolongation’ and ‘decrease in tumour 
size’ as achieved in 37%, 41% and 44% respectively. The goal of ‘cure’ was mentioned three 
times by oncologists. This number was too small to include in the analysis.
Figure 1. Flowchart recruitment of patients and oncologists. * From the included 266 patients, 19 
patients participated twice for different lines of therapy. ** For 6 of the 266 patients the oncologist did 





 146 patients filled out the questionnaire after 
treatment (61%) 
94 patients did not fill out the questionnaire (39%) 
 72 patients died during treatment (30%)
o 25 chemotherapy (10%)
o 38 immunotherapy (16%)
o 9 TKIs (4%)
 22 patients declined to fill out the
questionnaire after treatment (9%)
o 11 patients were too ill (5%)
o 11 patients did not fill out after
several reminders (5%)
266 patients filled out the 
questionnaire before treatment* 
23 oncologists filled out the questionnaire 
after treatment for 223 patients (95%) 
23 oncologists filled out the questionnaire 
before treatment for 260 patients** 
Oncologists did not fill out the questionnaire for 11 
patients (5%) 
 4 questionnaires were not filled out after
several reminders (2%)
 7 questionnaires were not filled out since
oncologists moved to another hospital (3%)
26 patients were still on 
the same treatment (10%) 
240 patients finished the treatment within the 
study period (90%) 
26 patients were still on 
the same treatment (10%) 
23 oncologists had 234 patients who finished 
the treatment within the study period(90%) 
376 eligible patients with (N)SCLC 
stage IV approached 
     110 patients were not included (29%) 
• 33 patients perceived it as too emotional
• 32 patients already died or stopped the 
treatment before filling out the 
questionnaire
• 3 2 patients did not hand in the 
questionnaire
• 1 3 patients reported another reason
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Table 1. Demographic characteristics of study participants
Variable Chemotherapy Immunotherapy TKIs Total
Patients; N (column %) N=61 (42% )** N=65 (44%) N=20 (14%) N=146 (100%)
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There were 72 patients who died during the treatment. The oncologists for these patients 
completed the questionnaire after treatment. They perceived their treatment goals for these 
patients to be achieved in 26% for ‘quality of life’, in 19% for ‘life prolongation’ and in 35% 
for ‘decrease in tumour size’ (data not shown).
Patient and care characteristics associated with achievement of treatment 
goals
Patients more often perceived their goal as achieved when they had a higher score on quality 
of life measures. Patients who received TKIs perceived their defined treatment goals as 
achieved less often than patients who received chemotherapy (table 2).
Both patients and oncologists perceived their treatment goals as achieved more often 
when the patient received a longer duration of treatment. In addition, for both patients and 
oncologists, there was no association between achievement of goals and whether the goal 
was ‘quality of life’, ‘life prolongation’, ‘decrease in tumour size’ or ‘cure’ (table 2 and 3).
In a sensitivity analyses using a cut-off score of 6 or more as having achieved a goal, there 
was no difference in the factors associated with goals being achieved compared to the 
primary analysis that used a cut-off score of 7 or more. Among patients, older age was also 
positively related to goals being achieved and among oncologists, receiving immunotherapy 
and having a higher ECOG performance score were negatively related to goals being achieved 
(See appendix table D and E).
Variable Chemotherapy Immunotherapy TKIs Total


















TKIs: Tyrosine Kinase Inhibitors; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung 
cancer; NSCLC: non-small cell lung cancer.
* Denotes more than 5% missing cases; education: 9%, ECOG performance score: 9%
** 6 patients who received a combined chemotherapy and TKI study treatment were included in the 
chemotherapy group
Bold values indicate a difference with a p-value of ≤0.05.
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The right decision to start treatment according to patients and oncologists
Seventy-nine percent (79%) of patients, in hindsight, felt that they had made the right decision 
to start a systemic treatment. Among patients who had achieved and not achieved their goals, 
92% and 72% respectively felt they had made the right decision to start systemic treatment. 
Oncologists felt they had made the right decision to start a systemic treatment in 96% of 
cases. Among cases where oncologists had achieved goals vs. not achieved goals, 100% and 
93% respectively felt they had made the right decision to start systemic treatment.
Further insight in achievement of treatments goals and starting a 
treatment was the right decision
Some patients mentioned in the interviews they perceived their goal as achieved if there 
seemed to be some positive effect on their treatment goal, e.g. slow progression of the 
tumour instead of the expected fast progression for the goal ‘to slow the cancer’. This often 
affected their health situation positively for a shorter or longer period of time. ‘Quality of life’ 
was perceived as achieved because patients’ quality of life was reasonable at that moment. 
(Table 4, Q1) One interviewed patient said that his goal ‘cure’ was achieved, because he still 
was alive (Table 4, Q2).
Figure 2. Achievement of treatment goals. * Patients (n=146) had 219 goals together, oncologists had 
428 goals together (for n=223 patients)
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Table 2. Univariate and multivariate GEE analyses of factors associated with achievement of treatment 


















1.219 (0.647 – 2.295)























1.387 (0.530 – 3.627)























0.520 (0.222 – 1.213)
0.478 (0.177 – 1.285)
Quality of life (mean ± stdev) 4.6 ± 1.6 1.716 (1.408 – 2.092) 1.545 (1.299 – 1.837)
Tumour histology
SCLC (13)
NSCLC without targetable driver 
mutation (152)






1.030 (0.156 – 6.790)
0.486 (0.086 – 2.752)








0.637 (0.280 – 1.453)
0.280 (0.090 – 0.872)
1.0
0.381 (0.133 – 1.090)









0.512 (0.351 – 0.747)









2.612 (1.187 – 5.750)
3.432 (1.075 – 10.957)
1.0
1.615 (0.784 – 3.327)






1.007 (0.557 – 1.822)
1.0
Treatment goal
Quality of life (69)








0.871 (0.293 – 2.594)
1.910 (0.927 – 3.937)
2.263 (1.120 – 4.573)
OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value 
of ≤0.10 for the univariate model and with a p-value of ≤0.05 for the multivariate model. 
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Table 3. Univariate and multivariate GEE analyses of factors associated with achievement of treatment 
goals according to oncologists 
N=428
Variable (N)
Goal achieved  
(≥7) according  to 













0.422 (0.201 – 0.886)
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0.661 (0.373 – 1.170)
0.343 (0.140 – 0.838)
Quality of life (mean ± stdev) 4.6 ± 1.6 1.355 (1.112 – 1.653)
Tumour histology
SCLC (25)
NSCLC without targetable 
driver mutation (296)






1.211 (0.745 – 1.970)
2.456 (1.121 – 5.378)








0.763 (0.266 – 2.184)









0.864 (0.479 – 1.558)









5.905 (2.437 – 14.312)
47.651 (13.742 – 165.229)
1.0
5.905 (2.437 – 14.312)
47.651 (13.742 – 165.229)











Other patients mentioned that they perceived their goal as not achieved when the treatment 
had a negative effect and when their health situation had deteriorated. For example, the 
goal ‘cure’ had not been achieved because the treatment had not affected the size of the 
tumour, or the goal ‘best possible quality of life’ had not been achieved because the patient 
permanently lost all energy due to the treatment.
Although some patients stated that they were deeply disappointed when treatment goals had 
not been achieved, they thought, in hindsight, it was the right decision to start. They had at 
least tried to achieve their goal in every way possible, because they actively did something 
to slow the progression of disease, and because ‘doing nothing’ was not a reasonable option. 
(Table 4, Q 3-4).
Similar to patients, oncologists perceived their goals as achieved if there was any positive 
effect on the patients’ well-being, whether this was a small or large effect (Table 4, Q5). 
Treatment goals were perceived as not achieved when the situation of a patient quickly 
deteriorated, which could also be due to a side effect of the treatment (Table 4, Q6).
Oncologists were disappointed when treatment goals were not achieved, but explained why 
they often perceived their decision as right in hindsight. First, they mentioned that any one 
specific patient could have been the one who turned out to be an exception– most often in 
terms of life extension and therefore, it was the right decision to start treatment (Table 4, 
Q7). Also, at the start of treatment it seemed to be the right decision at that time. Additional 
reasons noted by oncologists for perceiving starting a treatment as ‘the right decision’ in 
hindsight were that guidelines or the patients’ wish had been followed (Table 4, Q8 and Q9).
N=428
Variable (N)
Goal achieved  
(≥7) according  to 










1.367 (0.619 – 3.022)
1.0
Treatment goal
Quality of life (171)







1.147 (0.890 – 1.476)
OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value 
of ≤0.10 for the univariate model and with a p-value of ≤0.05 for the multivariate model. 
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Table 4. Quotes of patients and oncologists on achievement of goals and why it was the right decision 
to start treatment
No Quotes of patients 
Q1 I: Let me proceed to the questionnaire after treatment, we discuss your treatment goals 
here: a bit longer, better life with some quality. And then we ask you: to what extent is this 
achieved, rate it with a number? And your answer is, an 8, because, preserved quality.
P: Yes, that is the same as I just mentioned. I feel that right now I, have a reasonable 
quality of life. With some restriction off course. But I consider myself blessed that I am still 
clear headed, that I can experience everything, watch TV and Netflix, you name it. I read a 
book…
(Patient with goal ‘quality of life’ achieved)
Q2 I: And if the question is if your goal is achieved, the goal “cure”. What do you mean with 
the number 8, did you achieve the goal than or not…
P: I achieved the goal a little bit. I am still alive, yes, good. But what if the immunotherapy 
works, than I still have some time to live. There is still hope. The current status, how it is 
right now. Yes.
(Patient with goal ‘cure’ achieved)
Q3 “You cannot say in advance, I only have 9 months and I throw in the towel. That is nothing 
for me. (…) And if I do something, than at least I do something. (…) It will bring something, 
for me or for the doctors or both. That’s how I think about it.
(Patient with goal ’stop cancer’ not achieved) 
Q4 I: Let’s see the questionnaire, here is the question: in hindsight, do you think that this was 
de right treatment. You say: if you don’t do it, you know for sure that it doesn’t work.
P: Yes, not trying is no option. And also the hope right.  
(Patient with goal ‘cure’ not achieved)
No Quotes of oncologists
Q5 I: Then the questionnaire after the treatment. That one show something else. You rate the 
goal decrease tumour growth as achieved with the number 9.
P: Yes, it worked.
I: Yes, did that work?
P: Yes, a 9 is achieved.
I: And then you say in your questionnaire: I feel that this was the right decision because 
at first I have seen a response. That 9, can you tell me how that went and what that 9 
means?
P: That 9 means just, we have tried to decrease the tumour, and that worked. That tumour 
has become smaller. And that means, look, if you can decrease the growth of the tumour, 
it means that the tumour delays. That it will grow thereafter, so to say. But you have 
bought some time then. That is what it is all about. 
Q6 I: In the questionnaire after the treatment you report at ‘goal achieved’ a 0 for the goal 
stop and decrease the tumour .
P: Yes, this man also got Hepatitis. Therewith he deteriorated enormously. I made him 
worse instead of better [looks sad]” 
Q7 P: If that [deterioration] is out of question and the patient feels himself well and you still 
have a treatment to come and he looks fit…. (…) There is also reality. Seriously, I have 
patient who live for 10 years with stage 4.
I: You have examples, that it works.






The treatment goals that patients defined when starting the treatment ‘quality of life’, ‘life 
prolongation’, ‘decrease in tumor size’ and ‘cure’ were perceived as achieved in 30%, 49%, 
26% and 44% respectively. For oncologists treatment goals were perceived to be achieved 
in 37%, 41% and 44% of cases, respectively. Patients with a higher score on quality of life 
measure and patients who received treatment for more than six months more often perceived 
their treatment goals as achieved than other patients. Patients who received TKIs were less 
likely to feel they achieved their treatment goals. Oncologists more often perceived their 
treatment goals as achieved for patients receiving treatment for two months or more. We 
found no association between achievement of goals and whether the goal was ‘quality of 
life’, ‘life prolongation’, ‘decrease in tumour size’ or ‘cure’. Most patients and oncologists, 
in hindsight, felt they had made the right decision to start treatment whether or not they 
had not achieved their goals. An important reason for this was that they at least had tried 
something. 
Most treatment goals are not achieved
It is noticeable that the majority of treatment goals were not achieved from the perspective of 
both the patients and oncologists. In prior work we found that both patients and oncologists 
when starting a treatment sometimes doubted feasibility of achieving their treatment goals 
even when they gave a relatively high score on feasibility. It appeared that hope was more 
important in considering a treatment feasible than actual chances on success.10, 17 In the 
current study, the goal ‘decrease in tumour size’ was much less often reported as achieved 
Q8 P: You know in advance that the chance that this treatment succeeds for all goals you 
mention here, is 20 percent. But that is the best chance you have. According to the gui-
delines that is your right decision. But you also know in advance that it won’t work for 80 
percent of the patients. And this patient sadly belong to the 80 percent of people for who 
it doesn’t help. So in hindsight it didn’t go wrong. Only what you had hoped or predicted, 
didn’t come through.
Q9 I: And then I see, we ask in the questionnaire, is the right decision made in hindsight to 
start this treatment, then you say yes because there were no other options…
P: Yes, another option would have been not starting treatment [laughs]
I: Yes that was wat I wondered by seeing these questions.
P: Yes but sometime someone really doesn’t want that. And she didn’t received any treat-
ment yet I think, no systemic treatment, most of the time people want to try something, 
at least the people that we see. So in that aspect it was the right treatment for her, yes 
in hindsight it didn’t worked for her. So the specific treatment was in itself a good choice. 
Only you could have also argued, the condition is too bad we don’t do it.
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by patients (26%) compared to oncologists (44%). It could be that oncologists report this goal 
as achieved with even small decreases in the size of the tumour, while patients only consider 
substantial decrease as achieving this goal. Only 1 out of 3 patients and oncologists perceived 
‘quality of life’ as achieved. This is of concern, as quality of life is often mentioned as important 
aspect in the last phase of life. Interestingly, among the 27 patients who identified ‘cure’ as 
a treatment goal, 44% (12 patients) reported this goal as achieved. This goal is unrealistic as 
metastatic lung cancer cannot be cured and might be a form of hope. This is supported by 
patient statements in our qualitative interviews (see table 4, Q2).
It seems logical that patients with higher quality of life perceive their goals more often as 
achieved as they probably feel better. However, it is less straightforward why this is the case 
for the other goals. A possible explanation for the fact that patients who received TKIs less 
often achieved their treatment goals might be related to the fact that TKI’s are often seen as 
a promising treatment18; higher expectations might lead to more disappointment and lower 
achievements scores. The finding that for both patients and oncologists treatment goals are 
more often achieved when the treatment duration is longer, is likely to be related to treatment 
being stopped when the condition of the patient worsens. 
Patients and oncologists feel starting the treatment was the right decision
Four out of five patients (79%) and oncologists (96% of cases) felt, in hindsight, that they 
had made the right decision to start treatment. The qualitative interviews showed that 
wanting to do ‘something’ was an important factor for both patients and oncologists in 
feeling that starting treatment was the right decision. This importance of doing ‘something’ 
resonates with other studies.19, 20 There are few previous studies that evaluate satisfaction 
with treatment decisions among advanced cancer patients.21 Visser et al. found that 86% of 
patients with advanced lung cancer indicated that they would decide to undergo the same 
treatment again, regardless of deterioration or improvement in quality of life.21 Umihara et 
al. found that among patients who had received cancer treatment, 67% of patients were 
satisfied with their decision, and that satisfaction was related to good patient physician 
communication.22  Hitz et al. found among patients with advanced cancer 73% satisfaction 
with treatment decision.23
Strengths and limitations 
Strengths of our study include the contribution of both academic and non-academic hospitals, 
use of open-ended questions for respondents to formulate goals in their own words and the 
additional interviews to better understand respondents answers. A limitation of our study 
is that we only interviewed patients and oncologists from the academic hospital, possibly 
giving bias to the additional information. 
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Conclusion and implications 
Our finding that most patients and oncologists, in hindsight, feel starting treatment was the 
right decision while indicating that most treatment goals were not achieved is not easy to 
interpret. One could interpret this as a good outcome because patients and oncologists feel 
they made the right decision. However, even when not considering the cost of treatment, 
one can question whether starting treatments that are likely not to achieve stated goals are 
in the best interest of patients. The interviews indicate that wanting to do ‘something’ was 
important for both patients and oncologists in their assessment that starting treatment was 
the right decision. This suggests that if there were other options to do something that had 
a higher possibility of reaching goals, this might be preferable. When the goal is quality of 
life, which was achieved only in 1 in 3 patients, palliative care could be such an option. In 
addition, when the goal is life prolongation, (concurrent) palliative care is a good option as 
several studies have shown that early initiation of palliative care can prolong life.24, 25 In order 
for these approaches to work in practice it is important that treatment options, including 
their benefits and side-effects, are discussed in advance of treatment decisions. It is key that 
these discussions include not only systemic treatment, but palliative care as effective options 
for doing ‘something’. Our results could provide valuable input for these discussions.
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APPENDIX
Ques�onnaire for pa�ents:  
- “Before the treatment, you mentioned the following treatment goals. To what 
extent are these goals achieved on a scale of 0 to 10?” 
1._[Goal 1 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
2._[Goal 2 is wri�en here ___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
3._[Goal 3 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
4._[Goal 4 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
-  “In retrospect, did you receive enough information on the treatment?”  
Too much/ enough/ not enough 
This is what I missed: __________________ 
 
- “In hindsight, do you think the right decision was made for treatment?”  
Yes/ No / I don’t know for sure 
 
- Did the treatment goals you had before the start of treatment, change during 
treatment? 





Figure A. Questionnaires for patients and oncologists
Ques�onnaire for oncologists: 
-  “Before your patient started the treatment, you mentioned the following 
treatment goals. To what extent are these goals achieved on a scale of 0 to 
10?” 
1._[Goal 1 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
2._[Goal 2 is wri�en here ___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
3._[Goal 3 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
 
4._[Goal 4 is wri�en here]___________________________________ 
0    1    2    3    4    5    6    7    8    9    10 
not achieved at all                    highly achieved 
- “In hindsight, do you think the right decision was made for treatment??”  




Achievement of treatment goals in metastatic lung cancer patients
Table A. Examples of treatment goals from patients and oncologists
Category English
Quality of life Having a more comfortable life
Better quality of life
Better mobility
Feeling better
Being able to do more things than I can do now
The best quality of life
Making the quality of life as high as possible
Having a bearable life
Having a pleasant life
Good quality of life
Quality of life
Improve quality of life
Improve life
Strive for a better life than I have now








Being less ill 




To stop cancer cells from growing
To stop the cancer
To prevent the cancer from growing
To control cancer
That the cancer disappears
To decrease the tumour cells
That the tumour disappears
That it does not grow any further
High stabilization of the disease
To fight the cancer
Prevent new metastases
To stop the tumour from growing
To delay the cancer process
To stop the cancer
Stopping the disease process
To shrink the tumour
To slow down the disease







To withhold the tumour
To shrink the tumour
To delay the growth
Life prolongation Better life opportunities
To live longer



















Other Visiting Suriname 
Nothing
To keep the option for radiation
To quit 
To do everything about it
Improve medication for future patients
To contribute to science 
So that specialists can learn 
To have the feeling I have tried everything 
Gain more insight in research 
To keep the option for immunotherapy
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Table C. Comparison of patients who filled out questionnaire or not


































































NSCLC without targetable 
driver mutation (170)














































ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; TKIs: 
Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value of ≤0.05.
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Table D. Univariate and multivariate GEE analyses of factors associated with achievement of treatment 
goals according to patients
N=219
Variable (N)
Goal achieved (≥6) 














1.661 (0.908 – 3.041)
1.937 (0.908 – 4.131)
1.0
4.938 (2.249 – 10.846)























0.775 (0.361 – 1.662)























0.848 (0.323 – 2.225)
0.755 (0.291 – 1.959)
Quality of life (mean ± stdev) 4.6 ± 1.6 1.927 (1.482 – 2.507) 2.001 (1.501 – 2.667)
Tumour histology
SCLC (13)
NSCLC without targetable driver 
mutation (152)






1.247 (0.168 – 9.248)
1.056 (0.151 – 7.375)








0.684 (0.289 – 1.617)
0.516 (0.262 – 1.018)
1.0
0.489 (0.165 – 1.446)









0.615 (0.355 – 1.067)









2.617 (1.323 – 5.179)
4.966 (1.871 – 13.185)
1.0
2.176 (0.990 – 4.785)






1.169 (0.526 – 2.595)
1.0
Treatment goal
Quality of life (69)








0.792 (0.321 – 1.955)
0.950 (0.424 – 2.133)
2.233 (1.134 – 4.337)
OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value 
of ≤0.10 for the univariate model and with a p-value of ≤0.05 for the multivariate model. 
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Table E. Univariate and multivariate GEE analyses of factors associated with achievement of treatment 


















0.489 (0.266 – 0.900)























0.685 (0.444 – 1.056)























0.573 (0.348 – 0.942)
0.310 (0.142 – 0.678)
1.0
0.468 (0.217 – 1.009)
0.338 (0.114 – 1.000)
Quality of life (mean ± stdev) 4.6 ± 1.6 1.518 (1.286 – 1.792)
Tumour histology
SCLC (25)
NSCLC without targetable 
driver mutation (296)






0.673 (0.241 – 1.880)
1.358 (0.376 – 4.902)








0.711 (0.287 – 1.761)
2.869 (1.461 – 5.634)
1.0
0.356 (0.153 – 0.829)









0.783 (0.437 – 1.401)









6.817 (3.747 – 12.403)
72.613 (19.245 – 273.970)
1.0
7.356 (3.298 – 16.407)
134.476 (25.721 – 703.069)













1.006 (0.452 – 2.237)
1.0
Treatment goal
Quality of life (171)







1.065 (0.868 – 1.307)
OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer; 
NSCLC: non-small cell lung cancer; TKIs: Tyrosine Kinase Inhibitors. Bold values indicate a difference with a p-value 
of ≤0.10 for the univariate model and with a p-value of ≤0.05 for the multivariate model.
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Abstract
Objective: Lung cancer has a high impact on both patients and relatives due to the high 
disease burden and short life expectancy. Previous studies looked into treatment goals 
patients have before starting a systemic treatment. However, studies on relatives’ perceptions 
of treatment at the end of life are scarce.
Aim: Therefore, we studied the perspectives of relatives in hindsight on the achievement of 
treatment goals and the choice to start treatment for metastatic lung cancer of their loved 
one.
Methods: We conducted a structured telephone interview study in six hospitals across the 
Netherlands, one academic and five non-academic hospitals, between February 2017 and 
November 2019. We included 118 relatives of deceased patients diagnosed with metastatic 
lung cancer who started a systemic treatment as part of usual care (chemotherapy, 
immunotherapy or targeted therapy with tyrosine kinase inhibitors (TKIs)) and who completed 
a questionnaire on their treatment goals before the start of treatment and when treatment 
was finished. We asked the relatives about the achievement of patients’ treatment goals and 
relatives’ satisfaction with the choice to start treatment. This study is part of a larger study in 
which 266 patients with metastatic lung cancer participated who started a systemic treatment 
and reported their treatment goals before start of the treatment and the achievement of 
these goals after the treatment.
Results: Relatives reported the goals ‘quality of life’, ‘decrease tumour size’ and ‘life 
prolongation’ as achieved in 21%, 37% and 41% respectively. The majority of the relatives 
(78%) were satisfied with the choice to start a treatment and even when none of the goals 
were achieved, 70% of the relatives were satisfied. About 50% of relatives who were satisfied 
with the patients’ choice mentioned negative aspects of the treatment choice, such as the 
treatment did not work, there were side effects or it would not have been the relatives’ 
choice. Whereas, 80% of relatives who were not satisfied mentioned negative aspects of the 
treatment choice. The most mentioned positive aspects were that they tried everything and 
that it was the patient’s choice.
Conclusion: The majority of relatives reported patients’ treatment goals as not achieved. 
However, relatives were predominantly satisfied about the treatment choice. Satisfaction 
does not provide a full picture of the experience with the treatment decision considering 
that the majority of relatives mentioned (also) negative aspects of this decision. At the time 
of making the treatment decision it is important to manage expectations about the chance 




Lung cancer is the world’s leading cause of cancer death.1 For patients with metastatic lung 
cancer chemotherapy, immunotherapy and targeted therapy with tyrosine kinase inhibitors 
(TKIs) are possible palliative systemic treatments with the aim of relieving symptoms, 
temporary disease control and prolonging survival.2-5
People at the end of life often have diverse physical, psychological and social needs, as well 
as a need to prepare for death and achieve peace at the end of life.6-8 While patients and 
relatives attach great value to fulfilling these needs8, at the same time there is often hope 
for a cure or life prolongation.9, 10
Three studies found the following treatment goals that patients mentioned before starting 
treatment for metastatic lung cancer: ‘improve or maintain quality of life’, ‘prolong life’, ‘find 
comfort’, ‘fight cancer’ and ‘cure cancer’.11-13 In a previous study we found that after treatment 
patients reported in less than 50% of time that these goals were achieved: ‘quality of life’ for 
30%, ‘life prolongation’ for 49%, ‘decrease tumour size’ for 26% and ‘cure’ for 44%. Directly 
after the treatment was finished most patients felt, in hindsight, that starting treatment was 
the right decision, even if the treatment goals were not achieved.10 
Metastatic lung cancer has a large impact on both patients and relatives.14, 15 Relatives often 
accompany patients to a physician visit and help the patients obtain information relevant to 
medical treatments.16-18 Relatives might have an alternative opinion to the patient regarding 
the choice to start treatment and whether the goals were actually achieved. The relatives 
witness the patient with metastasized lung cancer from diagnosis to death, and they are 
able to take into account the last phase of life when considering whether treatment goals 
are achieved and if the right choice was made. Additionally, the relative has a different 
perspective since they are not the patient.
Since metastatic lung cancer also affects the life of patient’s relatives and not much is known 
on their views in hindsight the objectives were to study the perspective of relatives on the 
choice to start lung cancer treatment, after the patient had deceased. We specifically focussed 
on (1) relatives’ perspective regarding achievement of patients’ treatment goals, (2) relatives’ 
view on the patients’ choice to start treatment and (3) the relation between the achievement 
of treatment goals and satisfaction with the patient’s choice to start treatment.
Methods
Study design and population
The present study is an explorative sub-study of a larger prospective study on achievement of 
the goals metastatic lung cancer patients and their oncologists have when starting a palliative 
systemic treatment as part of usual care (chemotherapy, immunotherapy or targeted therapy 
with tyrosine kinase inhibitors (TKIs)).10 During the patients’ informed consent procedure in 
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the previous study, patients and relatives were asked to choose a relative to participate in 
the present study if the patient is deceased. Inclusion criteria were ability to give informed 
consent, possessing a telephone and willing to participate. During the structured telephone 
interview with relatives of deceased metastatic lung cancer patients we asked to what extent 
they felt that the goals patients had when starting a systemic treatment were achieved. The 
telephone interview was conducted with relatives a minimum of 6 weeks after the patient 
had died, which we feel is an appropriate time frame to be able to recall the treatment, but it 
not too early after a loved one has passed. To enhance the rigor in the study, the researcher 
who interviewed the relatives was transparent, i.e. not the treating physician of the patient. 
Additionally, the interviews were all conducted in the same way, following the same order 
in the questionnaire and performed by one researcher (AM, between February 2017 and 
November 2019).
Data collection
The structured telephone interview schedule was developed based on the questionnaire 
for patients and oncologists (see appendix 1). During the structured telephone interviews, 
questions were read aloud and answers were written down textually. The interviews were 
not audio recorded. The interviews focused on the treatment goal(s) the patient reported 
before the start of treatment. During the interview relatives were asked to what extent they 
perceived the patients’ treatment goal(s) as achieved on a scale from 0 to 10, with 0 as not 
achieved at all and 10 as completely achieved. Additionally, relatives were asked if they were 
satisfied with the patients’ choice to starting treatment and whether the relatives thought 
they received enough information on the given treatment of the patient (see appendix). The 
relatives’ age, gender and relation to the patient were documented.
The time between the patient’s death and the interview with their relative was on average 86 
days, with the exception of one relative that was interviewed 15 days after the patient died, 
instead of 6 weeks after the patient died, because the investigator did not know the patient 
had already died when she called for the study among patients. The relative preferred to 
do the interview at that time rather than later. The time between the last administration of 
treatment the patient received and the interview with the relative was on average 201 days.
Ethics, consent and permission.
This study was approved by the medical ethical committee (METc) of the VU University 
Medical Centre in Amsterdam, the Netherlands (number NL57455.029.16). Both patients 
and relatives gave written consent to participate in the study and for patients to have their 




Descriptive statistics were conducted using IBM SPSS statistics 24. We perceived a goal as 
achieved if it was rated with a 7 or higher (on a 0 to 10 scale). This was based on the semi-
structured interviews performed in the previous study in which we asked the patients to what 
extent they felt their treatment goals were achieved on a scale from 0 to 10.19 The question 
on the satisfaction with the treatment choice in hindsight was to be answered with ‘yes’, 
‘no’ or ‘I am not sure’ and additionally open-ended for further explanation. The answers 
‘no’ and ‘I am not sure’ were for analysis merged into ‘not satisfied’. Answers to this open-
ended question were categorized independently and subsequently compared by 4 research 
members (HRWP, BDO, AM, AB). The codes agreed upon were grouped in the categories 
‘positive aspects’, ‘negative aspects’ and ‘other aspects’. Discrepancies were resolved through 
discussion until 100% agreement was achieved.
Results
Participant recruitment 
In total, 266 patients started a treatment for metastatic lung cancer and completed the 
questionnaire on their treatment goals. Of these patients, 164 patients were deceased during 
the study period, resulting in 164 relatives being eligible for participation of which 118 (72%) 
participated in an interview (figure 1). Refusing of participation during the informed consent 
procedure was in most of the cases because the patient didn’t want to bother their relatives 
with the study in which he or she participated. Decline in participation during the telephonic 
interview was because the relative already died, telephonic number was not in use or the 
phone was not picked up after trying several times on different days and times.
Characteristics of study participants
Participants had an average age of 62 years and ranged between 30 and 85 years. Most 
participants were female (63%) and the partner of the patient (81%) (table 1). Length of the 
interview was not recorded but roughly lasted between 5 and 60 minutes with an average 
time of 15 minutes.
Achievement of patients’ treatment goals according to relatives  
 The 118 relatives of patients reported about the achievement of 143 treatment goals with an 
average of 1.2 goals per patient and a maximum of three goals. In total, 21 patients mentioned 
‘cure’ as a treatment goal. Since only the relatives of deceased patients were included, we did 
not ask if the goal ‘cure’ was achieved so we excluded this treatment goal from the analysis. 
Relatives overall most often reported the achievement of the treatment goal with 0 (not 
achieved at all) (n=47). Relatives reported the goals ‘quality of life’, ‘life prolongation’ and 
‘decrease in tumour size’ as achieved in 21%, 41% and 37% respectively (figure 2). 
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Figure 1. Flowchart of participants. The red box concerns the participants in the current study which 
is part of a larger study in which 266 patients with metastatic lung cancer participated. In that study, 
patients could participate multiple times in the study resulting in 247 individual patients from whom 
the relatives could be approached. Only relatives of deceased patients were eligible to participate. In 
the end, 118 relatives participated in this interview study. * Consent from patient and relative was asked 
at the start of the treatment. ** Patients were allowed to participate twice in the questionnaire study 

















266 questionnaires on patients’ treatment goals* 
164 eligible relatives (100%) 
118 relatives were interviewed by telephone (72%) 
8 relatives did not answer for several times (5%) 
38 relatives and/or patients had not given 
permission at the start of the study  (23%) 
 
126 relatives approached for telephonic interview (77%) 
247 relatives of patients who started a treatment for 
metastatic lung cancer and completed the questionnaire 
on their treatment goals  
    19 patients participated twice for another treatment** 
 
    83 patients were alive at the time of the analysis 
































In total, 76 relatives (64%) perceived none of the goals as achieved, 42 relatives (36%) 
reported that at least one of patients’ goals was achieved, and 29 relatives (25%) reported 
that all goals were achieved (data not shown).
Satisfaction with patients’ choice to start treatment
A total of 78% (n=92) of the relatives was, in hindsight, satisfied with the patients’ choice 
to start treatment, 14% (n=16) was not satisfied about the treatment choice and 9% (n=10) 
was not sure.
Figure 2. Achievement of the patients’ treatment goals according to relatives on a scale from 0 to 10 
with 0 meaning ‘not achieved at all’  and 10 meaning ‘totally achieved’. These number are dichotomized 
into achieved and not achieved with a cut off score of 7. * Relatives (n=118) had answered on 143 












0 1 2 3 4 5 6 7 8 9 10
Achievement of patients' treatment goals 
according to relatives (%) n=143*
QOL (n=54) Life prolongation (n=46)







0% 20% 40% 60% 80% 100%
Decrease tumour size (n=43)
Life prolongation (n=46)
Quality of life (n=54)
Not achieved ≤ 6 Achieved ≥ 7
Achieved ≥ 7 Not achieved ≤ 6  
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When asked to explain why they felt satisfied or not with the patients’ treatment choice, 42% 
of relatives reported only positive aspects, 31% reported both positive and negative aspects 
and 27% reported only negative aspects. Relatives that were satisfied with the treatment 
choice did not only mentioned positive aspects: 30% mentioned both positive and negative 
aspects and 22% mentioned only negative aspects. Furthermore, relatives that were not 
satisfied did not only mentioned negative aspects: 36% mentioned both positive and negative 
aspects and 20% mentioned only positive aspects.
The most frequently mentioned positive aspects were ‘we tried everything’ (24%), ‘it was 
the patient’s choice’ (14%), and ‘the patient lived longer’ (14%). ‘It was the patient’s choice’ 
was more frequently mentioned by relatives that were not satisfied with the treatment 
choice than relatives that were satisfied (23% versus 12%). ‘The patient lived longer’ was 
more frequently mentioned by relatives who were satisfied than relatives who were not (16% 
versus 4%). The most frequently mentioned negative aspects were ‘the treatment did not 
work’ (19%), ‘there were side effects’ (13%), and ‘it was not my choice’ (10%). Next to positive 
and negative aspects relatives also mentioned other aspects, which were often related to the 
quality of care. Insufficient quality of care was more frequently mentioned by relatives who 
were not satisfied than relatives who were (23% versus 10%). Good quality of care was only 
mentioned by relatives that were satisfied (21%) (table 2). Most of the relatives (78%) were 
satisfied with the choice to start a treatment (n=92). From the relatives who reported that 
at least one of patients’ goals was achieved (n=42), 93% were satisfied about the treatment 
choice. When none of the goals were achieved (n=76), 70% of the relatives were satisfied.
Examples of explanation of relatives who answered ‘satisfied about the treatment choice’ 
and mentioned:
• Only positive aspects:
You try to get hope with the treatment. He had no side effects, as with chemotherapy. 
However, he progressed after a couple of cycles. We started the treatment to stall/extend. 
Every 3 weeks. Eventually he passed away through euthanasia, he wanted to keep control in 
his own hands (in the categories ‘It gives hope’ and ‘no side effects; relative of deceased 
patient, age between 50 and 60 years).
• Positive and negative aspects:
It was my husbands’ choice, so that is good. But for me, it all went really fast. Doctors 
repeatedly said: it is going fine. Then, after surgery on his chest wound it suddenly went 
wrong and he quickly past away. It is really unfortunate/a shame, and I was angry, because 
we did not speak the oncologists when my husband was admitted to the hospital. No call, 
no visit. We had to hear from the ward doctor that there were no treatment options left 
and he would have very short time left (to live). But, he still had a good summer after the 
immunotherapy so that is nice (in the categories ‘It was the patients’ choice’, ‘good quality 
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of life’ and ‘insufficient quality of care’; relative of deceased patient, age between 60 
and 70 years).
• Only negative aspects:
In the final period we had our doubts. The exams took long and in the meantime the cancer 
kept growing in the liver. After 3 months of radiation of the lungs nothing happened. In 
the medical files it said palliative chemotherapy, however, this was not mentioned to us 
(curative). Chemotherapy is still junk, in hindsight the last chemotherapy was too much 
(in the categories ‘The treatment was started too late’ ‘insufficient quality of care’ and 
‘treatment was given too long’; relative of deceased patient, age between 40 and 50 
years).
Table 2. Positive and negative aspects mentioned by relatives on patients’ choice to start treatment










•  Only positive aspects
•  Positive and negative aspects











•  We tried everything
•  It was the patients’ choice
•  Lived longer
•  The treatment worked
•  No side effects
•  It gives hope



























•  The treatment didn’t work
•  Side effects
•  It was not my choice
•  Quality of life worsened
•  Treatment was given too long
•  Burdensome hospital visits























•  Good quality of care
•  Insufficient quality of care
•  It was the choice of the oncologists
•  I don’t know how it would have been 
otherwise
















*Including relatives who reported “not sure” on the treatment satisfaction. 
** 4% missing. Percentages don’t add up to 100% since more answers were possible.
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Examples of relatives who answered ‘not satisfied about the treatment choice’ and 
mentioned:
• Only positive aspects:
It was his choice. He lived longer because of the chemo. His wife wanted to try. But at a 
certain point he did not want to anymore, also no immunotherapy unless it was possible 
from home (in the categories ‘Lived longer’ and ‘choice of the patient’; relative of 
deceased patient, age between 50 and 60 years).
• Positive and negative aspects:
My husband was so ill and he already received so many treatments. There were no more 
treatment options left, he felt like a test subject, it is tough, traveling long distance and 
we kept going/continued too long. In [other hospital] they also continue treatment for a 
long time. But everyone tries to grab on every straw/chance (in the categories ‘We tried 
everything’, ‘quality of life worsened’, ‘insufficient quality of care’ and ‘burdensome 
hospital visits’; relative of deceased patient, age between 70 and 80 years).
• Only negative aspects:
It didn’t work. She still had lots of treatments after this one. From the chemo she only lost 
her hair/ turned balled (in the categories ‘The treatment didn’t work’ and ‘side effects’; 
relative of deceased patient, age between 60 and 70 years).
Discussion
Relatives reported the goals ‘quality of life’, ‘decrease tumour size’ and ‘life prolongation’ as 
achieved in 21%, 37% and 41% respectively. Most of the relatives (78%) were satisfied about 
the patients’ choice to start treatment. Even if none of the goals were achieved, 70% of the 
relatives were satisfied. In total, 52% of relatives who were satisfied with the patient’s choice 
mentioned negative aspects of the treatment choice, such as the treatment did not work, 
that there were side effects or that it would not have been the relatives choice. While 80% 
of relatives who were not satisfied with the patient’s choice to start treatment mentioned 
negative aspects. The most mentioned positive aspects were that they tried everything and 
that it was the patient’s choice. In total, 31% of relatives reported both positive and negative 
aspects of the treatment choice, independently of being satisfied or not.
Relatives consider patient’s treatment goals less often achieved than patients.
The patients for whom the relatives reported whether the treatment goals were achieved 
reported their predefined treatment goals ‘quality of life’, ‘decrease tumour size’, and ‘life 
prolongation’ achieved in 30%, 26% and 49% respectively.10 Thus, compared to patients, 
relatives consider the goals ‘quality of life’ (21% vs 30%) and ‘life prolongation’ (41% vs 
49%) less often achieved and ‘decrease tumour size’ (37% vs 26%) more often achieved. 
This difference could firstly be due to the fact that relatives reported the achievement of 
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goals after the patient died taking into account the whole illness. For the goal ‘quality of 
life’, for example, it might be that at the time the treatment stopped (the time point that 
the patient reported the achievement of goals) the quality of life of the patient was higher 
compared to the last phase of life. The latter was most likely the reference point for relatives 
when they considered whether the goal ‘quality of life’ was achieved. Secondly, relatives 
may have a different perspective on quality of life because they have their own believes 
and considerations to undergo or forgo cancer treatment than patients. Thirdly, they do not 
have the disease themselves, which may also influence their perspective. Fourthly, when 
looking at the negative aspects, relatives mentioned side effects and worsened quality of 
life. It might also be that from the perspective of relatives it is very difficult seeing their loved 
one deteriorate and suffer and therefore more often report the goal ‘quality of life’ as not 
been achieved. Finally, it is known that relatives tend to assess a patient’s quality of life as 
somewhat lower than what the patient perceives.20, 21
Satisfaction with treatment decision is linked to negative feelings about treatment decision.
Most of the relatives were, in hindsight, satisfied about the patients’ choice to start treatment 
(78%), even if none of the goals were achieved (70%). These results are comparable to 
the patients’ and oncologists’ view regarding making the right decision to start treatment 
(patients: 79% and oncologist: 96%) even if none of the goals were achieved (patients: 72% 
and oncologists: 93%) in the previous study of Mieras et al.10 it is known that measuring 
satisfaction is not without problems. It holds the risk of creating a positive bias which could, 
for instance, be influenced by the desire to give a socially desirable answer or, according 
to cognitive dissonance theory, a tendency to assess one’s situation or actions as good in 
hindsight.22, 23 Nevertheless, the fact that we found over half of people who were satisfied 
with the treatment decision described negative aspects related to the decision taken shows 
that satisfaction does not encompass the relatives’ entire experience. The most mentioned 
negative aspects were that the treatment did not work and that there were burdensome 
side effects of the treatment. These negative aspects should be taken into account when 
deciding to start a treatment with a relatively low chance of success and high chance of side 
effects e.g. by managing expectations of patients and relatives with clear communication and 
highlighting the option of palliative or supportive care to treat side effects.
Next to negative aspects related to the treatment decision taken, many relatives also 
mentioned positive aspects. It was most frequently mentioned that it was positive the patient 
tried everything. Previously, we found that this was also an important aspect for the patients 
and oncologists.10 Additionally, it was important for many relatives that the patients’ wish for 
treatment was followed, even when the relatives themselves felt that the treatment might 
have gone on for too long. Notably, none of the positive aspects we found resonated with 
aspects valued at the end of life found in a study by Steinhauser et al.: ‘pain and symptom 
management’, ‘clear decision making’, ‘preparation for death’ and ‘completion’ valued at the 
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end of life.8 This might be related to the fact that in our study we focused on the evaluation 
of the decision to start systemic treatment. For patients who start with treatment and their 
families, it might be more difficult to prepare for death than for people who do not start 
treatment. It might also be that they value the aspects at the end of life less.
Strengths and limitations
A strength of this study is that it provides new insights in the perspective of the relative on 
the treatment for an incurable disease of their loved one; we could not find studies which 
results we could compare to ours. Furthermore the contribution of both one academic and 
five non-academic hospitals (multi-centre and a case mix of patients) and the adequate 
number of participants at a difficult time willing to share information on a sensitive subject 
contribute to the validity of the results. Another strength is that through the structured 
telephone interviews with open questions, the relatives were allowed to elucidate positive 
and negative aspects on the treatment satisfaction. Since all interviews were conducted by 
one researcher continuity is assured, however, it may also cause interpretation bias which 
can be seen as a limitation. Another limitation might be that the researcher wrote down 
the answers during the telephone interview and might not have managed to capture all the 
details, instead of when the conversations were audio recorded.
Conclusions
The majority of relatives reported patients’ treatment goals as not achieved. However, 
relatives were predominantly satisfied about the treatment choice. Satisfaction of treatment 
choice does not encompass the entire experience with the treatment decision since the 
majority of relatives mentioned negative aspects of this decision. At the time of making 
the treatment decision it is important to manage expectations about chance of success and 
possible side effects of the treatment. Relatives, like patients, find it important to feel that 
something is being done, thus, it can be beneficial to not contrast the option of systemic 
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Relatives’  views on the achievement of treatment goals
GENERAL DISCUSSION7
The overall aim of this thesis is to gain more insight into systemic treatment for patients with 
metastatic lung cancer in the context of the end of life. Research aims are to study:
• The percentage of metastatic lung cancer patients who receive chemotherapy or TKIs in 
the last month of life in the Netherlands.
• The percentage of metastatic lung cancer patients who die inside the hospital and whether 
hospital death is associated with receiving systemic treatment in the last month of life.
• The type and feasibility of treatment goals that patients and their oncologists have when 
starting systemic treatment.
• To what extent patients’ and oncologists’ treatment goals are achieved after systemic 
treatment and whether this differs between types of therapy. In addition, whether it was 
the right decision to start treatment in hindsight.
• The perspective of the relatives in hindsight on the achievement of the patients’ treatment 
goals and whether they are satisfied about the patients’ treatment choice.
This final chapter will discuss the findings of the studies described in the previous chapters. 
Firstly, some methodological considerations will be formulated. Secondly, the main findings 
of the previous chapters and the interpretation of the results will be discussed. Finally, several 
implications of this thesis for clinical practice and future research will be considered.
Methodological considerations
To answer the objectives of this thesis two studies were conducted: a multicentre 
retrospective patient file study in ten hospitals in the Netherlands (chapter 2 and 3) and a 
multicentre prospective longitudinal questionnaire study in patients, their oncologists and 
their relatives in six hospitals in the Netherlands (chapter 4 – 6). 
Retrospective patient file study
The patient file study performed in ten hospitals in the Netherlands included 1322 files of 
patients diagnosed with metastatic lung cancer who died between 2013 and 2015. The data 
from this study was collected retrospectively.
A strength of this study is the high number of patients analysed (n=1322) across ten different 
hospital sites; this makes the results robust and generalizable. By including 3 academic 
hospitals and 7 non-academic hospitals distributed across the North, East, South and West 
of the Netherlands, we assume that it is a representative sample of the Dutch metastatic lung 
cancer population. Selection bias is minimized because all patients diagnosed with metastatic 
lung cancer were included in this study, assuming that diagnose codes were administered 
correctly and that all patients with lung cancer have a file in their hospital.
132
Chapter 7
However, this study has some potential limitations. The inevitable limitation of a patient 
file study is that the files are the only source of information. Therefore, false information is 
hard to detect and missing values cannot be filled up. Also, some files may be incomplete 
because patients went to another hospital for care. Specifically for our study, we were 
able to extract the information on the systemic treatment patients received, however, we 
were unable to discover the rationale behind the patient’s and the oncologist’s choice to 
start and stop chemotherapy or TKIs. We had information on several possible covariates or 
confounders, but this was not complete. For instance, data on performance status could not 
always be retrieved from medical records due to the absence of documentation. Patients 
with a poor performance status might have a higher risk of hospitalization and consequently, 
hospital death. Other potentially relevant covariates or confounders are symptom burden, 
date of diagnosis, ethnicity and socioeconomic circumstances, among others. Lastly, we only 
documented the last systemic treatment line, therefore we have no knowledge on how many 
or which systemic treatments patients received in earlier treatment lines.
Longitudinal questionnaire study
The longitudinal questionnaire study was performed between November 2016 and April 2018. 
We included 266 patients with metastatic lung cancer who received a systemic treatment 
(chemotherapy, immunotherapy or targeted therapy with tyrosine kinase inhibitors (TKIs)), in 
either an academic or a non-academic hospital in the Netherlands. We chose a longitudinal 
design to follow the patients throughout their disease course and ask them to what extent 
they feel their goals were achieved and whether it was a good decision to start a systemic 
treatment in hindsight. Additional semi-structured interviews were performed with 15 
metastatic lung cancer patients and 5 treating oncologists from one academic hospital.
One part of the longitudinal questionnaire study was a structured telephonic interview to 
gain insight into the perspective of the relatives on the systemic treatment for an incurable 
disease of their loved one. We conducted telephonic interviews between February 2017 
and November 2019 including 118 relatives of deceased metastatic lung cancer patients 
who started a systemic treatment in either an academic or a non-academic hospital in the 
Netherlands and who completed the questionnaire on their treatment goals before start of 
the systemic treatment.
Strengths of this study are the large sample size of patients, the case mix of both one 
academic and five non-academic hospitals, the use of open ended questions so that patients 
and oncologists had to formulate the treatment goals in their own words and the additional 
semi-structured interview to better understand respondents answers. Also, because both 
patients and oncologists filled out a questionnaire simultaneously but independently from 
each other, the answers to the questionnaires could be compared between patients and 




after the systemic treatment started and therefore limited any recall bias, whereas other 
studies mostly ask about treatment goals in retrospect.
A strength of the interview study is that we gained information on all patients, including 
patients who were not able to fill out the questionnaire after treatment due to rapid 
progression of the disease or sudden death. In this way we have information on the disease 
process of 118 patients in the period between the ending of the systemic treatment and 
death.
A limitation is that in the semi-structured interview study, we only interviewed patients and 
oncologists from the academic hospital, possibly giving bias to the additional information. 
These patients are a selective group who more often than in non-academic hospitals wish 
to start a systemic treatment. The questionnaire on treatment goals was written in Dutch; 
therefore, only Dutch-speaking patients could participate. This resulted in a cohort of patients 
with mostly a Dutch cultural background, while it is known that people with a migration 
background sometimes have other views on treatment decisions in the last phase of life.1,2 
About 15 non Dutch-speaking patients were excluded for participation on this ground. We 
did not receive all questionnaires after systemic treatment since some patients died during 
the treatment; In other cases, the disease progressed so rapidly there was no time to ask 
the patient to fill out the questionnaire after treatment. Therefore, only the patients with a 
relatively stable condition filled out the questionnaire after the systemic treatment, which may 
result in higher treatment goal achievement scores. However, we do have the questionnaires 
from the oncologists of the patients who died and did not fill out the questionnaire so 
information on this patient group is available.
A limitation of the interview study was that the interview was on average about three months 
after the patient died and on average over half a year after the last systemic treatment the 
patient received. The long time between these events and the interviews might create recall 
bias resulting in different views over time. Also, views on treatment might be emotionally 
loaded because of the last phase of life.
An overall limitation of both studies is that due to rapid evolvements in systemic treatments 
the current guidelines have been changed. The analysis of the patient file study is somewhat 
outdated with the introduction of immunotherapy and the analysis of the longitudinal 
questionnaire study is outdated with the combination of chemotherapy and immunotherapy 
as current guideline. Analysis of current data might yield different results, however, these 
results are still valuable and give insight into systemic treatments at the end-of-life.
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Main findings and interpretation of the results
The main findings in this thesis are that: 
• 18% of metastatic lung cancer patients received chemotherapy (11%) or TKIs (7%) in the 
last month of life. Of the patients who received chemotherapy in the last month of their 
life, 54% started this systemic treatment in the last month of life,
• 18% of metastatic lung cancer patients died in the hospital and in-hospital death was 
associated with a relatively late use of chemotherapy or targeted therapy,
• patients and oncologists set various goals for the systemic treatment they receive/
prescribe; respectively: ‘quality of life’ (45%; 72%), ‘life prolongation’ (45%; 55%), 
‘decrease in tumour size’ (39%; 66%) and ‘cure’(19%; 2%), with patients having slightly 
higher feasibility scores on their treatment goals compared to oncologists (6.8 vs 5.8 on 
a 10-point scale),
• most goals patients and oncologists had when starting a systemic treatment were not 
achieved after treatment; the goals ‘quality of life’, ‘life prolongation’, ‘decrease in tumour 
size’ and ‘cure’ were achieved in 30%, 49%, 26% and 44% for patients and in 37%, 41%, 
44% and 0% for oncologists, respectively. Additionally, 79% of patients and almost all 
oncologists (96%) felt, in hindsight, that they had made the right decision to start the 
treatment, even if they had not achieved their goals, with the main reason that ‘doing 
something’ was important,
• compared to patients, relatives consider the goals ‘quality of life’ (21% vs 30%) and ‘life 
prolongation’ (41% vs 49%) less often achieved and ‘decrease tumour size’ (37% vs 26%) 
more often achieved. Most relatives (78%) were satisfied with the patients’ choice to 
start a systemic treatment, even if none of the goals were achieved (70%). However, 
satisfaction with the treatment choice does not always cover the entire experience. Aside 
from positive aspects related to the decision to start a systemic treatment, many relatives 
also mentioned negative aspects, like ‘the treatment did not work’.
Receiving a systemic treatment at the end of life
The retrospective patient file study showed that 18% of metastatic lung cancer patients 
received a systemic treatment in the last month of life (11% chemotherapy and 7% TKIs). 
The percentage of patients receiving chemotherapy in the last month of life is comparable to 
percentages found for patients with lung cancer in other studies.3-10 For patients receiving TKIs 
in their last month of life, we showed that 71% did not carry a targetable driver mutation. TKIs 
are said to have less life threatening side effects compared to chemotherapy, lead to fewer 
hospital visits and show a rapid response.11-18 However, the response rate is low in patients 
without a targetable driver mutation and non-life threatening side effects are common, so 
it is debatable whether this should be considered good practice.19 The downside of these 




the patient’s quality of life.12,20-22 Cancer immunotherapy was only introduced in 2015, thus 
our study did not include patients who were treated with immunotherapy. However, a more 
recent study shows that 27% of palliative cancer patients who received immunotherapy, 
received this treatment in the last 30 days of life.23 
Additionally, we found that out of the patients who received chemotherapy in the last 
month of their life, 54% started this treatment in the last month of life. In the interviews of 
the longitudinal questionnaire study, we observed that patients start a systemic treatment 
because they want to do everything to fight the disease and it gives them a form of hope. 
This has also been shown in other studies.24,25 Furthermore, starting a systemic treatment may 
be a coping strategy for patients to deal with their approaching death. Buiting et al. reported 
that some patients regard chemotherapy-free periods to be more stressful than periods of 
treatment.26 The semi-structured interviews and other studies show that oncologists may 
offer further treatment and strive for life prolongation since they might need to feel like they 
have to do something.27 This was seen in a study of Van Leeuwen et al., oncologists preferred 
to continue a systemic treatment rather than withhold it despite doubts that the treatment 
benefits actually outweigh the burdens.28
The patient file study also showed that 18% of metastatic lung cancer patients died in the 
hospital and in-hospital death was associated with the relatively late use of chemotherapy 
or targeted therapy. This result confirms findings from earlier studies that receiving 
chemotherapy in the last month of life is associated with a reduced likelihood of home 
death.22,29,30 Regarding hospital deaths, it was shown that in 2008 28% of lung cancer patients 
died inside the hospital in the Netherlands.31 However, the number of hospital deaths in the 
Netherlands is relative low compared to the rest of the world, with a large variation across 
countries from 26% (Netherlands and New Zealand) to 87% (South Korea).32 Knowledge 
about these numbers are informative since place of death is often regarded as an important 
parameter for quality of care.33 Literature shows that most patients prefer to die at home33-
38 and satisfaction with end-of-life care is improved when patients die in their preferred 
location.39 It has been shown that receiving systemic treatments shortly before death may 
result in potential burdensome and increased hospital admissions and consequently hospital 
deaths, which could be a threat to good end-of-life care.40-42
Treatment goals of patients and oncologists for starting a systemic treatment
In the previous paragraphs we showed that a substantial percentage of metastatic lung 
cancer patients received a systemic treatment, even close to death, which could be seen 
as aggressive end-of-life care. However, in the longitudinal questionnaire study we see that 
patients are intrinsically willing to start these treatments. When asking about the goals of 
treatment, patients and oncologists reported ‘quality of life’ (45%; 72%), ‘life prolongation’ 
(45%; 55%), ‘decrease in tumour size’ (39%; 66%) and ‘cure’ (19%; 2%) respectively. These 
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results in combination with the semi-structured interview study show that patients may 
choose intensive systemic treatment that might have limited benefits and major toxicity in 
order to try anything that might improve their quality of life or prolong their life, which is 
also shown in literature.43,44
Although 82% of patients reported discussing their treatment goals with their oncologists and 
91% of oncologists reported discussing goals with their patients, we found low concordances 
between patients’ and oncologists’ goals: with 24% for ‘decrease in tumour growth’ and 37% 
for ‘quality of life’. A recent study by Douglas et al. showed that patients with advanced cancer 
and their oncologist also had a low concordance on the goals ‘survival’ (8.3%) and ‘quality 
of life’ (15%).45 Other studies found much higher rates of patient-oncologist concordance in 
treatment goals ranging between 68% and 72%.46-48 However, these studies consisted of a 
heterogeneous cancer population with various disease stages. We found multiple possible 
explanations for the low concordance out of the semi-structured interviews and literature. 
First, it might be that there is discrepancy in the importance of patients’ and oncologists 
goals and therefore in the goals they remember to have discussed. Second, it is possible 
that an oncologist does not emphasize the direct goal in the questionnaire but more the 
ultimate goal in the discussion with the patient (or vice versa). Third, oncologists might 
not want to mention goals that are not feasible because it would discourage the patient 
and cause emotional distress. Fourth, oncologists may use complex language and report 
treatment goals to patients in an euphemistic and optimistic manner. Fifth, despite clear 
communication from the oncologist regarding their view on the treatment, patients might 
not be able to fully process the information or they might interpret the aim of the treatment 
more positively than it was intended. It is well known that patients poorly absorb information 
after being diagnosed with a life-threatening disease. However, it might also be that patients 
and oncologists actually had different goals, without misunderstanding.49-54
The longitudinal questionnaire study also showed that patients had slightly higher feasibility 
scores on their treatment goals compared to oncologists (6.8 vs 5.8 on a 10-point scale). From 
the interviews, it appeared that most patients mentioned hope as an explanation for a high 
feasibility score before treatment. This might also explain the rather high feasibility score of 
7,0 for the treatment goal cure. It became clear that oncologists may also influence hope; 
their willingness to start a systemic treatment fed patients’ hope for cure or life prolongation 
as seen in the interviews. Other studies also showed that patients were more optimistic about 
their prognosis and treatment goals compared to their oncologists.55,56
Achievement of treatment goals and the right decision to start a systemic treatment in 
hindsight
The treatment goals that were defined by patients and oncologists when starting a systemic 




According to patients these were achieved in 30%, 49%, 26% and 44% respectively, according 
to oncologists in 37%, 41%, 44% and 0% respectively and according to relatives in 21%, 41%, 
37% and 0% respectively. No difference was found between the type of systemic treatment 
and treatment goals. 
The goal ‘decrease in tumour size’ was rarely reported as achieved by the patients (26%) and 
less often reported compared to the oncologists (44%) and relatives (37%). It could be that 
oncologists and relatives report this goal as achieved with a small decrease in tumour size, 
while patients only consider a substantial decrease as achievement of this goal. It may also 
be that a goal focussed on fighting the cancer is linked to other goals in the minds of patients 
but not overtly expressed. This could indicate that goals might be hierarchical, with lower 
order goals serving to achieve more important higher order goals. However, more importantly, 
this specific goal might not seek the specific end of decreasing the tumour size but serve as 
a reason to do everything that is possible to fight the disease.
Patients and oncologists perceived the goal ‘quality of life’ as achieved in 30% and 37% 
respectively, while according to relatives, this goal was achieved in only 21%. A possible 
explanation might be that the side effects of the treatment actually decreased the quality of 
life in most cases.12,20-22 This is alarming because quality of life is regarded as most important 
in the last phase of life and it highlights that communication between patients and oncologists 
about the treatment goals and their feasibility is hugely important. It might also be that from 
the perspective of relatives, it is very difficult seeing their loved one deteriorate and suffer 
and, therefore, more often report the goal ‘quality of life’ as unachieved. Overall, it is known 
that relatives tend to assess a patient’s quality of life as somewhat lower than the patients’ 
assessment.57,58 However, patients with a higher score on their quality of life questionnaire 
more often perceived their treatment goals as achieved; not only the goal ‘quality of life’, but 
also the other goals. It is logical that patients with higher quality of life more often perceive 
their goals as achieved as they probably feel better. 
Interestingly, from the 27 patients who had ‘cure’ as treatment goal, 44% (12 patients) 
reported this goal as achieved. This goal is unrealistic since metastatic lung cancer cannot be 
cured. In the previous paragraph we mentioned that for patients hope can play an important 
role in setting ‘cure’ as a treatment goal, therefore, hope could be a coping strategy. However, 
when asking about the achievement of the goal ‘cure’ in the interviews, one patient answered 
‘the oncologists said that the scan was good’. It seems that this patient misunderstood the 
message of the oncologist, since he or she was not cured. This emphasizes the necessity 
of communication with specific discussions on systemic treatments with palliative intends 
instead of curative intend. 
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The achievement of treatment goals when using Tyrosine Kinase Inhibitors (TKIs) is a topic 
worth to discuss. From the retrospective patient file study, we concluded that a substantial 
percentage of metastatic lung cancer patients received TKIs. However, in the longitudinal 
questionnaire study, we saw that most of the treatment goals that patients had were not 
achieved when they were treated with TKIs. If we look at the treatment goals for different 
systemic treatments received, we see that most patients who received TKIs reported ‘quality 
of life’ as a goal. TKI’s are often seen as a promising treatment, due to less life threatening 
side effects and a higher response rate compared to chemotherapy. Therefore, patients might 
hope for an increase in quality of life with this treatment.59 However, higher expectations 
might lead to more disappointment and lower achievement scores. The continuation of TKIs 
towards the end of life may be due to an overestimation of the likelihood of survival and 
underestimation of side effects by oncologists. It might also be a result of the fact that it is 
often easier to recommend a new line of treatment than to discuss cessation of treatment.60,61 
Alternatively, it may also be attributed to the disease flare associated with the discontinuation 
of TKIs.11 Therefore, patients might hold unrealistic expectations of new treatment options 
and cherish even small survival benefits.43
In hindsight, 80% of patients felt that they sufficiently discussed their goals at the start 
of treatment with their oncologists. This number is much higher compared to a study by 
El-Jawahri et al. where only 22% of patients reported discussing their wishes with their 
oncologists.62 Additionally, 79% of patients, almost all oncologists (96%) and 78% of the 
relatives felt, in hindsight, that they had made the right decision to start treatment, even 
if they had not achieved their goals. The qualitative interviews showed that wanting to do 
‘something’ was important for both patients and oncologists when justifying that starting 
treatment was the right decision. However, satisfaction with the treatment choice does not 
always cover the entire experience. More than halve of relatives who were satisfied also 
mentioned that the treatment did not work, that there were side effects or that it was not 
their choice. These negative aspects should be taken into account when deciding to start a 
systemic treatment with a low chance of success and high chance of side effects. One possible 
way to do this is by managing expectations of patients and relatives with clear communication 
and highlighting the beneficial potential of palliative care to treat symptoms of the cancer. It 
also has been shown that when patients had end-of-life discussions, bereavement adjustment 
for families was better.63
Interpretations of the results
This thesis shows that a substantial number of metastatic lung cancer patients receive a 
systemic treatment in the last month of life and that both patients and oncologists are 
intrinsically motivated to start a treatment to try everything to fight the disease. Even if 
treatment goals are not achieved, most of the patients and oncologists are satisfied with 




something’ approach is the best option for these palliative patients or that alternative options 
such as palliative care are more suitable. Multiple studies have evaluated systemic treatments 
at the end of life and receiving and even starting chemotherapy in the last month of life is 
generally seen as aggressive care. It often goes along with more visits to the emergency 
department and the intensive care unit and consequently more hospital deaths.6,22, 64-67 
Therefore, in 2012 the American Society for Clinical Oncology (ASCO) recommended palliative 
care to avoid the use of chemotherapy at the end of life and to improve patient care.68,69 
However, we found that after this recommendation was published, there is still a substantial 
percentage of patients receiving chemotherapy or TKIs in the last month of life.
Early palliative care (EPC) means early integration of palliative care c.q. care that is provided 
from diagnosis throughout the continuum of care. It consists of consultation with palliative 
care experts, advance care planning (ACP) and shared decision making (SDM).70-74 Since 
its introduction multiple studies have shown an association with a decreased use of 
chemotherapy at the end of life in metastatic lung cancer patients.72-79 Early integration of 
palliative care also enhances patients’ understanding of their illness and prognosis.80-82
Part of early palliative care is the discussion of treatment goals, which may increase patient-
oncologist communication, enabling patients to better identify and explain their treatment 
preferences and helping oncologists act according to those preferences.72,73,76 The fact that the 
results in the questionnaire study show that 19% of metastatic lung cancer patients reported 
‘cure’ as a treatment goal, makes it questionable how well these goals have been discussed. 
However, in the semi-structured interview study most of the patients who mentioned 
‘cure’ as a treatment goal reported this goal not as highly realistic. Outlining realistic goals 
that patients and families can look forward to may assist in maintaining hope in light of a 
life-threatening illness. Evidence demonstrates that early discussion of treatment goals in 
advanced cancer patients is associated with beneficial outcomes for patients resulting in 
potential cost savings.63,72,83
Palliative care cannot be optimal without open and clear discussions regarding the patients’ 
preferences. Advance care planning (ACP) is a dynamic and ongoing process to discuss 
patients’ values, goals and hopes and identify their future healthcare preferences. The 
objective of advance care planning is to make sure that possible treatments align with 
patient’s wishes. This can be done by determining the overall goal of medical care and discuss 
the interventions that should and should not be provided.84 Another important aspect of 
palliative care is the location in which patients wish to receive this care and the location in 
which they wish to die. ACP might help patients to gain insight into these wishes and timely 
discuss it with their treating physician.85
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Shared decision making (SDM) is an approach in which patients and oncologists discuss 
the best available evidence when facing decisions, while patients are assisted in expressing 
their preferences and become actively involved in decision making.86,87 SDM is seen as an 
important element of high quality cancer care with essential elements including patients’ 
values and understanding of treatment goals88-90 and is associated with improvements in 
patient satisfaction.91 For this type of decision making it might be beneficial to educate and 
train oncologists in communication around difficult clinical situations, using a conversation 
guide or a checklist to discuss treatment goals.76,92-95 Key elements that should be addressed 
are the understanding of the prognosis and the treatment goals. It is important to consider 
if starting systemic treatments that are unlikely to achieve treatment goals are in the best 
interest of patients. Thus, in patients with a low chance of responding positively to a systemic 
treatment, the focus should be put on improving their quality of life.
Additionally, it could be helpful to make use of a decision aid (DA) in shared decision making.96 
Decision aids are tools that help patients to come to the best decision by showing the available 
treatment options, clarifying values and providing information about the available options and 
their outcomes.97 DAs are available in various forms such as patient letters, videos, leaflets 
or computer programs to encourage patients to think about their treatment preferences.98 
DAs for metastatic lung cancer patients might be promising when asking patients about their 
treatment goals in an open-ended way allowing them to describe their goals and reveal 
patients’ beliefs, values and preferences. Oncologists are then able to clarify and confirm 
patients’ goals, discuss the clinical implications of these goals, determine whether all relevant 
goals have been considered and set priorities among goals when necessary, as recommended 
by Haberle et al.99
In conclusion, for patients with a life-threatening disease, early palliative care is important 
to concurrently treat the tumour as also the patient with the disease. This approach may 
result in improvement in symptom control and a carefully-weighed treatment decision that 
is closely related to the patients’ wishes.
Implications for clinical practice
Based on the interpretation of the results we highly recommend the implementation of early 
palliative care to avoid aggressive end-of-life care in metastatic lung cancer patients and give 
care aligned with the preferences of the patient. An important aspect of early palliative care 
are end-of-life discussions about the goals patients have for their systemic treatment. Before 
deciding on the treatment, there should be substantial discussions regarding the treatment 
options, their benefits and side-effects and the goals patients have, allowing physicians to align 
treatments with what is most important and realistic to the patient. Strategies to normalize 
end-of-life discussion as part of clinical practice, including decision aids and methods for 




presented in this thesis we designed factsheets for metastatic lung cancer patients and their 
treating oncologists (in Dutch) which could also be helpful in having these discussions.101,102 
These goals should be regularly evaluated and discussed from diagnosis on through the 
entire treatment trajectory to discuss how realistic these goals are. When treatment goals are 
no longer realistic or unachievable, oncologists should communicate this with patients and 
potentially withdraw the anticancer treatment, switching to palliative care alone. In addition 
to that, conversations about the preferred place of death should be integrated into end-of-life 
patient-oncologist conversations so that oncologists are aware of the patients’ preferences 
concerning place of death. Palliative care experts can play a big and important role in these 
end-of-life discussions, concerning treatment goal evaluation and preferred place of death. 
This can be done in the way of early palliative care, i.e. that palliative care experts regularly 
have these discussions with metastatic lung cancer patients early in the disease trajectory, 
or by involving palliative care consultants when needed in certain cases. The latter option is 
probably more feasible in the Netherlands as every hospital in the Netherlands is obliged to 
have a palliative team to support among others oncologists in delivering end-of-life care and 
to have end-of-life discussions with patients at the end of life when needed.100,101
Recommendations for future research
In the previous paragraph, we recommended to implement early palliative care to avoid 
aggressive end-of-life care in metastatic lung cancer patients. This is based on the findings 
presented in this thesis that 18% of metastatic lung cancer patients received a systemic 
treatment in the last month of life. However, these results are derived from a retrospective 
patient file study containing metastatic lung cancer patients who died between 2013 and 
2015. These patients are treated via treatment guidelines which are outdated compared 
to the current guidelines in the Netherlands, with the introduction of immunotherapy as 
second-line treatment for metastatic lung cancer patients since 2016 and the introduction 
of a combination of chemotherapy and immunotherapy as first-line treatment option since 
2019.103,104 Therefore, it would be interesting for future research to investigate the percentage 
of metastatic lung cancer patients who received a systemic treatment in the last month of 
life, which may generate different results compared to the results presented in this thesis. 
In the past decades, non-small cell lung cancer treatment had a breakthrough with Tyrosine 
Kinase Inhibitors (TKIs) targeted therapy.105 During the research described in this thesis, 
systemic treatment with TKIs was still emerging, therefore we recommend to investigate 
the consequences of the use of TKIs, especially shortly before death. This could be done in 
the retrospective manner as we did, however, results would be even more valuable if semi-
qualitative interviews would shed light on the rationale of starting and continuing TKIs (or 
other systemic treatments) in the last phase of life. Also, the amount of patients receiving 
TKIs in the last month of life and died inside the hospital could probably be investigated 
with higher numbers due to the increasing use of TKIs compared to the number reported in 
this thesis. These results would make it possible to consider whether not giving TKIs shortly 
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before death should be a quality indicator for appropriate end-of-life care, as is the case for 
chemotherapy.29
In the longitudinal questionnaire study we evaluated the treatment goals and patients’ 
retrospective view regarding the decision to receive systemic treatment for their metastatic 
lung cancer. However, because we were interested in the views of patients who received a 
systemic treatment, we excluded patients who opted for no systemic treatment. It would 
be interesting to discover the rationale and the view regarding the decision of the patients 
who opted for no treatment and compare it with the results of the patients who received a 
systemic treatment.
Final remarks
This thesis shows that a substantial percentage of metastatic lung cancer patients starts 
a treatment near the end of life. Additionally, in-hospital mortality is high in patients who 
received a treatment in the last month of life, while home is most often the preferred place 
of death. This thesis also shows that patients and oncologists want to do everything that 
is possible to fight the disease, including aggressive treatments which might decrease the 
quality of life of patients and hinder them from preparing for death. We suggest to have 
continuous communication between the patient and oncologist throughout the disease 
progress, discussing the treatment goals and how feasible these goals are. Palliative care 
should be integrated at the time of diagnosis to improve this communication and the quality 
of life of the patients and their families facing problems associated with life threatening illness. 
This may prevent and relieve suffering through the early identification, correct assessment 
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Appendix 1. Factsheet for patients and relatives
Doelen van behandeling bij uitgezaaide longkanker (1)
Longkanker is kanker die in de longen is ontstaan. Helaas wordt deze diagnose vaak pas 
vastgesteld als de ziekte al uitgezaaid en niet meer te genezen is
Meer dan de helft van de patiënten met uitgezaaide longkanker start nog een 




Welke behandeldoelen hebben patiënten en hun artsen als ze besluiten te starten met een 
behandeling voor uitgezaaide longkanker
• Geven bijwerkingen
• Kunnen door bijwerkingen 
de kwaliteit van leven 
verminderen 
• Onderdrukken de tumorgroei




















“Mijn leven verlengen”  
“Geboorte kleinkind meemaken”  
“Beter worden”  
“Hopen op een wonder”  









De meeste mensen met 
de diagnose 
uitgezaaide longkanker 
leven tussen de 
9 maanden tot 3 jaar











Behaald (%) Niet behaald (%)
37 44 41
63 56 59




Behaald (%) Niet behaald (%)
Vaak worden behandeldoelen van patiënten en artsen volgens henzelf en nabestaanden niet behaald. 
Dat het doel ‘genezen’ volgens patiënten behaald is, ook al zijn zij ongeneeslijk ziek, 













Doelen van behandeling bij uitgezaaide longkanker (2)
Ook al worden doelen niet behaald, patiënten, artsen en nabestaanden zijn 
toch tevreden met de keuze om de behandeling te starten
Bespreek uw behandeldoelen met uw arts
Deze factsheet voor patiënten is gebaseerd op gegevens uit het onderzoek 
“Beoogde en bereikte doelen van behandelingen in de laatste levensfase
 vanuit patiënten en artsen perspectief”, uitgevoerd door Amsterdam UMC
Amsterdam 2020. Zie ook https://palliatievezorgnoordhollandflevoland.nl/Projecten/Beoogde-en-bereikte-doelen
Dit onderzoek is gefinancierd door ZonMw en KWF kankerbestrijding
“Ik had geen keuze”
“Ik heb tenminste alles geprobeerd”
“Je weet niet hoe het anders was geweest”
van de patiënten is 
tevreden met de 
keuze van de 
behandeling
79% 96%
van de artsen is 
tevreden met de 
keuze van de 
behandeling
3 van de 4 9 van de10
patiënten zijn ook 
tevreden als de doelen 
niet behaald zijn
artsen zijn ook 







van de nabestaanden 
is tevreden met de 
keuze van de patiënt 
om te starten met 
behandelen
Patiënten: 
Dit kan ervoor zorgen dat de behandeling die u ontvangt goed past bij 
uw behoeften en tegelijkertijd realistisch is 
Schrijf bijvoorbeeld op wat voor u belangrijk is en bespreek dit in het 
volgende consult met uw arts   
Nabestaanden zien terugkijkend zowel positieve als negatieve aspecten van de behandeling 
+ -
“Alles is geprobeerd”
“Het was de keuze van de patiënt”
“Mijn naaste heeft langer geleefd”
“De behandeling is niet aangeslagen”
“Bijwerkingen”
“Het was niet mijn keuze”
J L  K 
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Appendix 2. Factsheet for health care professionals
Doelen van behandeling bij uitgezaaide longkanker (1)
Meer dan de helft van de patiënten met uitgezaaide longkanker 
start nog een systemische behandeling 
Welke behandeldoelen hebben patiënten en hun artsen als ze besluiten te starten met een 
behandeling voor uitgezaaide longkanker
• Geven bijwerkingen
• Kunnen door bijwerkingen 
de kwaliteit van leven 
verminderen 
• Onderdrukken de tumorgroei




















“Mijn leven verlengen”  
“Geboorte kleinkind meemaken”  
“Beter worden”  
“Hopen op een wonder”  
Factsheet voor zorgverleners – Amsterdam UMC, 2020











Behaald (%) Niet behaald (%)
37 44 41
63 56 59




Behaald (%) Niet behaald (%)
Vaak worden behandeldoelen van patiënten en artsen volgens henzelf en nabestaanden niet behaald. 
Dat het doel ‘genezen’ volgens patiënten behaald is, ook al zijn zij ongeneeslijk ziek, 









Behaald (%) Niet behaald (%)
Patiënten kunnen een gelimiteerd idee hebben over hun prognose en behandelopties
Temel et al., 2011; Weeks et al. 2012
69% 
begreep niet dat hun behandeling de kanker niet meer zou genezen 
14% 
van longkanker patiënten zou niet opnieuw voor chemotherapie kiezen 
Weeks et al. 2012, USA




Doelen van behandeling bij uitgezaaide longkanker (2)
Ook al worden doelen niet behaald, patiënten, artsen en nabestaanden zijn 
toch tevreden met de keuze om de behandeling te starten
Conclusies en aanbevelingen
Deze factsheet voor zorgverleners is gebaseerd op gegevens uit het onderzoek 
“Beoogde en bereikte doelen van behandelingen in de laatste levensfase
 vanuit patiënten en artsen perspectief”, uitgevoerd door Amsterdam UMC
Amsterdam 2020. Zie ook https://palliatievezorgnoordhollandflevoland.nl/Projecten/Beoogde-en-bereikte-doelen
Dit onderzoek is gefinancierd door ZonMw en KWF kankerbestrijding
“Ik had geen keuze”
“Ik heb tenminste alles geprobeerd”
“Je weet niet hoe het anders was geweest”
van de patiënten is 
tevreden met de 
keuze van de 
behandeling
79% 96%
van de artsen is 
tevreden met de 
keuze van de 
behandeling
3 van de 4 9 van de10
patiënten zijn ook 
tevreden als de doelen 
niet behaald zijn
artsen zijn ook 
tevreden als de doelen 
niet behaald zijn
78%
van de nabestaanden 
is tevreden met de 
keuze van de patiënt 
om te starten met 
behandelen
Patiënten: 
 Doelen van patiënten en artsen worden vaker niet dan wel behaald – dit geldt het vaakst 
voor het doel ‘kwaliteit van leven’
 De meeste patiënten, artsen en nabestaanden zijn achteraf tevreden met de keuze om te 
starten met een systemische behandeling, ook al is hun doel niet bereikt   
 Patiënten en artsen vinden het vooral belangrijk ‘iets’ te doen en geen kansen te missen
 Het is belangrijk dat doelen van starten met systemische behandeling uitgebreid worden 
besproken om te komen tot een keuze die goed past bij de behoeften van de patiënt en 
tegelijkertijd realistisch is  
 Mogelijk zijn er andere alternatieven binnen de palliatieve zorg voor het ‘iets’ doen dan 
starten met een systemische behandeling – zeker als het gaat om het bereiken van 
‘kwaliteit van leven’
Nabestaanden zien terugkijkend zowel positieve als negatieve aspecten van de behandeling 
+ -
“Alles is geprobeerd”
“Het was de keuze van de patiënt”
“Mijn naaste heeft langer geleefd”
“De behandeling is niet aangeslagen”
“Bijwerkingen”
“Het was niet mijn keuze”












Chapter 1 provides an introduction to the topic of this thesis: treating metastatic lung cancer 
at the end of life. Lung cancer is currently one of the most frequently diagnosed cancers 
worldwide. Systemic treatments such as chemotherapy, immunotherapy and targeted therapy 
with Tyrosine Kinase Inhibitors (TKIs) aim to relieve symptoms with temporary disease control. 
However, it may also cause side effects which may lead to a decreased quality of life. A trend 
towards increasing use of systemic treatments for metastatic lung cancer has been shown, 
often called ‘aggressive care’. Several studies have shown that treatment at the end of life 
may result in potential burdensome and inappropriate hospital admissions and consequently 
hospital deaths. For patients with metastatic lung cancer, treatment could be aimed at life 
extension or quality of life without any prospect of cure. However, many patients receiving 
chemotherapy for incurable cancers may not understand that the treatment is unlikely to 
be curative, which could compromise their ability to make treatment decisions in line with 
their treatment goals. In the last few decades, patients’ satisfaction has become an important 
endpoint in the assessment of quality of care. It is important for patients with metastatic lung 
cancer that their expectations are being met for the treatment they receive. Communication 
of oncologists is therefore of fundamental importance in the treatment decision process. It is 
known that oncologists may use difficult language to discuss prognosis and treatment options. 
Also, cancer has a large impact on relatives. As patients and their relatives go along the 
different phases of the treatment trajectory together, relatives’ evaluation on the treatment 
is also important and may differ from the patients’. 
Therefore this thesis aims to study:
• The percentage of metastatic lung cancer patients who received chemotherapy or TKIs in 
the last month of life in the Netherlands.
• The percentage of metastatic lung cancer patients who died inside the hospital and 
whether hospital death is associated with receiving systemic treatment in the last month 
of life.
• The type and the feasibility of treatment goals that patients and their oncologists have 
when starting systemic treatment.
• To what extent the patients’ and their oncologists’ treatment goals are achieved after 
systemic treatment and whether this differed between types of therapy. In addition, 
whether it was their right decision to start treatment in hindsight.
• The perspective of the relatives in hindsight on the achievement of the patients’ treatment 
goals and whether they are satisfied about the patients’ treatment choice.
Chapter 2 presents the percentage of metastatic lung cancer patients who receive 
chemotherapy or TKIs in the last month of life in the Netherlands. A retrospective patient file 
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study was conducted in 10 hospitals and included 1322 metastatic lung cancer patients who 
died between mid-2013 and mid-2015. We found that a substantial percentage of metastatic 
lung cancer patients received and even started a treatment in their last month of life. In total, 
39% of patients received no treatment for metastatic lung cancer, 52% received chemotherapy 
and 9% received TKIs. A total of 232 patients (18%) received treatment in the last month of 
life (11% chemotherapy, 7% TKIs). From the patients who received chemotherapy or TKIs, 
11% and 12% respectively started this treatment in the last month of life.
Chapter 3 reports on the percentage of metastatic lung cancer patients who died inside the 
hospital in the Netherlands and whether hospital death is associated with receiving systemic 
treatment in the last month of life. These results were retrieved from the retrospective patient 
file study described in chapter 2 and showed that 18% of patients died during a hospital 
admission. This percentage was higher for patients who received chemotherapy (42%) or TKIs 
(25%) in the last month of life. Furthermore, the results showed that patients younger than 
60 years of age, patients who received chemotherapy in the last month of life and patients in 
whom TKIs were started in the last month of life were more likely to die inside the hospital.
Chapter 4 focusses on the treatment goals patients and oncologists have when starting 
a systemic treatment, what the concordance of patients and oncologist is between these 
goals and how feasible they think these goals are. The results were based on a longitudinal 
questionnaire study. For this study 266 patients and their prescribing oncologists filled out 
a questionnaire about their treatment goals and their estimated feasibility of these goals 
immediately after the treatment was decided. Patients and oncologists reported ‘quality of 
life’ (45%; 72%), ‘life prolongation’ (45%; 55%), ‘decrease in tumour size’ (39%; 66%) and 
‘cure’ (19%; 2%) as treatment goals. Additionally, semi-structured interviews were performed 
in order to better understand patients’ and oncologists’ treatment goals and thoughts on 
feasibility. These interviews showed that the goal ‘cure’ appeared to be often as motivation 
to stay alive. Concordances between patients’ and oncologists’ treatment goals were low 
(ranging from 24% to 33%). Patients had slightly higher feasibility scores than oncologists 
(6.8 vs 5.8 on a 10-point scale) and we showed that educational level, age, religious views 
and performance status of patients were associated with treatment goals. 
Chapter 5 describes to what extent patients’ and oncologists’ treatment goals were achieved 
after systemic treatment and whether it was the right decision to start treatment in hindsight. 
For this study a part of the participants described in chapter 4 participated: 146 metastatic 
lung cancer patients and 23 oncologists for 223 patients, wo filled out a questionnaire after 
the treatment. The exact goal that the respondent had written down in the first questionnaire 
was copied: for each of these goals it was asked to what extent the goal was achieved and if 
it was the right decision to start this treatment. This data showed that according to patients 
and oncologists, treatment goals were achieved in 30% and 37% for ‘quality of life’, 49% 
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and 41% for ‘life prolongation’, 26% and 44% for ‘decrease in tumour size’ and 44% and 0% 
for ‘cure’ respectively. Most patients and oncologists, in hindsight, felt they had made the 
right decision to start treatment, also if they had not achieved their goals (72% and 93% 
respectively). Additionally, semi-structured interviews were performed in order to better 
understand patients’ and oncologists’ achievement of treatment goals and to give further 
insight in making the right decision to start treatment. We found that making the right 
decision to start treatment was related to the feeling that they had to do ‘something’.
Chapter 6 elaborates on the perspective of relatives in hindsight on the achievement of 
patients’ treatment goals and whether they are satisfied about the patients’ treatment choice. 
Structured telephonic interviews were conducted with 118 relatives of patients described in 
chapter 4, at least 6 weeks after the patient died. During the interview relatives were asked 
to what extent they perceived the treatment goal(s) of the patient as achieved and if they 
were satisfied with the patients’ choice for starting a systemic treatment. Relatives reported 
the goals ‘quality of life’, ‘decrease tumour size’ and ‘life prolongation’ as achieved in 21%, 
37% and 41% respectively. The majority of the relatives (78%) was satisfied with the choice 
to start a treatment; even when none of the goals were achieved, 70% of the relatives was 
satisfied. Most often relatives were positive about the patients’ treatment decision because 
they felt that the patient had tried everything to fight the disease and they wanted to support 
the patient’s choice.
Chapter 7, the General Discussion, starts off with methodological considerations of the 
research presented in this thesis. Strengths of the studies include the high number of patients 
and a representative sample of the population. The limitations include the lack of report 
on the preferred place of death for the retrospective patient file study, the selective group 
of patients being mostly treated in an academic hospital and the dichotomization of the 
feasibility and achieved score from a scale from 0 to 10 into yes and no for the prospective 
questionnaire study. Next, the general discussion provides a description of the main findings 
from each chapter in relation to previous research and reflect on treatment, place of death 
and preferred and achieved treatment goals of metastatic lung cancer patients. Also views 
of oncologists and relatives on treatment goals and treatment decision are discussed. In the 
closing part of the chapter, some recommendations for clinical practice and future research 
are described. These include the need for palliative care at the end-of-life, recent research 
on the percentage of treated metastatic lung cancer patients and further research on the 





Hoofdstuk 1 introduceert het onderwerp van dit proefschrift: de behandeling van patiënten 
met uitgezaaide longkanker in de laatste fase van hun leven. Longkanker is wereldwijd een 
van de meest gediagnosticeerde kankers. Systemische behandelingen zoals chemotherapie, 
immunotherapie en doelgerichte therapie met Tyrosine Kinase Inhibitors (TKIs) hebben 
als doel de symptomen te verminderen en de ziekte onder controle te brengen. Deze 
kunnen echter ook bijwerkingen veroorzaken en de kwaliteit van leven verminderen. Het 
behandelen van uitgezaaide longkanker komt steeds meer voor en wordt vaak ‘agressieve 
zorg’ genoemd. Dit omdat meerdere onderzoeken hebben laten zien dat behandelingen 
in de laatste levensfase van patiënten vaak de oorzaak zijn van belastende en ongewenste 
ziekenhuisopnames, die uiteindelijk kunnen leiden tot overlijden in het ziekenhuis. De 
behandeling van patiënten met uitgezaaide longkanker waar genezing geen optie meer is, 
kan gericht zijn op levensverlenging of kwaliteit van leven. Helaas begrijpen veel patiënten 
die ongeneeslijk ziek zijn en toch een behandeling krijgen, niet goed dat deze behandeling 
de kanker niet meer kan genezen. In dat geval kan het zijn dat hun behandeldoelen niet 
overeenkomen met de keuze van hun behandeling. Tevredenheid met de gekozen behandeling 
is in de afgelopen jaren steeds belangrijker geworden in de kwaliteit van zorg. Het is van 
belang dat de verwachtingen van patiënten met uitgezaaide longkanker overeenkomen 
met de mogelijke behandelresultaten. Bij de keuze voor een behandeling, is communicatie 
tussen patiënt en arts uitermate wezenlijk. Een bekend probleem is dat artsen moeilijke 
termen kunnen gebruiken wanneer zij de prognose en behandelopties bespreken. Een ander 
aandachtspunt is dat kanker ook van grote invloed is op de naasten. Bij het doorlopen van 
een behandeltraject is de ervaring van de naasten over dit traject ook belangrijk en mogelijk 
kan deze afwijken van die van de patiënt.
In dit proefschrift worden de volgende zaken onderzocht:
• Het percentage patiënten in Nederland met uitgezaaide longkanker die een systemische 
behandeling krijgt in de laatste levensmaand.
• Het percentage patiënten met uitgezaaide longkanker die in het ziekenhuis overlijdt en in 
hoeverre dit gepaard ging met een behandeling in de laatste levensmaand.
• Welke behandeldoelen patiënten en artsen hebben wanneer zij starten met een 
systemische behandeling voor uitgezaaide longkanker, hoe vaak deze doelen overeenkomen 
en hoe haalbaar deze doelen worden geacht.
• In hoeverre de behandeldoelen die patiënten en artsen hebben, behaald zijn na 
behandeling van uitgezaaide longkanker en of deze behandeling achteraf gezien een goede 
keuze was volgens hen.
• De mening van de naasten over het behalen van de behandeldoelen van de patiënt en in 
hoeverre zij tevreden zijn over de behandelkeuze van de patiënt.
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Hoofdstuk 2 geeft inzicht in het percentage patiënten met uitgezaaide longkanker die nog een 
behandeling met chemotherapie of doelgerichte therapie krijgen in de laatste levensmaand in 
Nederland. Hiervoor was een retrospectief dossieronderzoek opgezet in 10 ziekenhuizen. In 
dit onderzoek zijn de gegevens van 1322 patiënten opgenomen met de diagnose uitgezaaide 
longkanker die overleden waren tussen medio 2013 en medio 2015. We zagen dat een groot 
deel van de patiënten met uitgezaaide longkanker toch nog een systemische behandeling 
kreeg; een deel startte zelfs nog in de laatste maand van hun leven met een behandeling. 
In totaal kreeg 39% van de patiënten geen behandeling voor uitgezaaide longkanker, 52% 
kreeg chemotherapie en 9% kreeg doelgerichte therapie. Hiervan kregen 232 patiënten 
(18%) de behandeling in hun laatste levensmaand, 11% chemotherapie en 7% doelgerichte 
therapie. Van de patiënten die chemotherapie en doelgerichte therapie ontvingen, startten 
respectievelijk 11% en 12% deze behandeling in de laatste maand van hun leven.
Hoofdstuk 3 rapporteert over het percentage patiënten met uitgezaaide longkanker in 
Nederland dat in het ziekenhuis overlijdt. Tevens is onderzocht of deze plaats van overlijden 
geassocieerd is met het ontvangen van een systemische behandeling in de laatste 
levensmaand. Deze resultaten komen uit het retrospectieve dossieronderzoek beschreven 
in hoofdstuk 2. Het blijkt dat 18% van de patiënten overlijdt in het ziekenhuis. Dit percentage 
was hoger voor patiënten die chemotherapie (42%) of doelgerichte therapie (25%) ontvingen 
in hun laatste levensmaand. Ook blijkt dat patiënten die jonger zijn dan 60 jaar, patiënten 
die chemotherapie in de laatste levensmaand ontvingen en patiënten waarbij doelgerichte 
therapie in de laatste levensmaand werd gestart, een grotere kans op overlijden hadden.
Hoofdstuk 4 toont de behandeldoelen die patiënten en artsen hebben wanneer zij starten 
met een systemische behandeling voor uitgezaaide longkanker. Daarbij is geanalyseerd hoe 
vaak deze doelen overeenkomen en hoe haalbaar zij deze doelen achtten. Deze resultaten zijn 
gebaseerd op een longitudinaal onderzoek. Voor dit onderzoek vulden 266 patiënten en hun 
artsen direct na het starten van de behandeling een vragenlijst in over hun behandeldoelen 
en de haalbaarheid. Patiënten en artsen gaven ‘kwaliteit van leven’ (45%; 72%), ‘langer 
leven’ (45%; 55%), ‘verminderen van de tumor’ (39%; 66%) en ‘genezing’ (19%; 2%) aan als 
behandeldoelen. Daarnaast waren er semigestructureerd interviews uitgevoerd om meer 
inzicht te krijgen in de behandeldoelen en haalbaarheid van patiënten en artsen. Het blijkt 
dat het doel ‘genezing’ vooral een motivatie was om in leven te blijven. Overeenkomsten 
tussen de doelen van patiënten en die van de artsen waren gering, tussen de 24% en 33% 
per doel. Patiënten hadden over het algemeen een hogere haalbaarheidsscore ten opzichte 
van artsen (6.8 t.o.v. 5.8 op een 10 punt-schaal). We lieten tevens zien dat opleidingsniveau, 




Hoofdstuk 5 beschrijft in hoeverre de behandeldoelen van patiënten en artsen behaald waren 
na een systemische behandeling voor uitgezaaide longkanker en in hoeverre die behandeling 
achteraf gezien een goede beslissing was. In dit onderzoek heeft een deel van de populatie uit 
hoofdstuk 4 deelgenomen: 146 patiënten met uitgezaaide longkanker en 23 artsen voor 223 
patiënten, die na de behandeling een vragenlijst ingevuld hadden. Van ieders behandeldoel 
dat de patiënt en arts vooraf hadden opgeschreven werd gevraagd in hoeverre dit behaald 
was en of het achteraf gezien de juiste behandelkeuze was. Volgens patiënten en artsen, zijn 
de behandeldoelen behaald in respectievelijk 30% en 37% voor ‘kwaliteit van leven’, in 49% 
en 41% voor ‘langer leven’, in 26% en 44% voor ‘verminderen van de tumor’ en in 44% en 
0% voor ‘genezing’. De meeste patiënten en artsen vonden achteraf gezien in 72% en 93% 
dat ze een juiste behandelkeuze hebben gemaakt. Dit zelfs wanneer de behandeldoelen niet 
werden behaald. Ook zijn er semigestructureerde interviews uitgevoerd om meer inzicht te 
krijgen in het behalen van de behandeldoelen en waarom het een goede keuze was om te 
starten met de behandeling. Hieruit blijkt dat een goede keuze voor de behandeling te maken 
heeft met het gevoel van ‘iets doen’ tegen de ziekte.
Hoofdstuk 6 presenteert de mening van de nabestaanden over het behalen van de 
behandeldoelen van de patiënt en in hoeverre zij tevreden zijn over de behandelkeuze van 
de patiënt. Gestructureerde, telefonische interviews zijn uitgevoerd met 118 nabestaanden 
van de populatie uit hoofdstuk 4, minimaal 6 weken nadat de patiënt overleden was. Daarbij 
is hen gevraagd of de behandeldoelen van de patiënt behaald zijn en of zij tevreden zijn met 
de behandelkeuze van de patiënt. Nabestaanden gaven aan dat de doelen ‘kwaliteit van 
leven’, ‘verminderen van de tumor’ en ‘langer leven’ respectievelijk behaald zijn in 21%, 37% 
en 41%. De meerderheid (78%) is tevreden over de behandelkeuze. Zelfs wanneer volgens 
hen geen enkel behandeldoel behaald was, was alsnog 70% tevreden. Nabestaanden zijn 
meestal positief over de beslissing om te starten met een behandeling omdat zij van mening 
zijn dat de patiënt alles heeft geprobeerd om de ziekte te bevechten en omdat ze deze keuze 
ondersteunen.
Hoofdstuk 7, de algemene discussie, begint met methodologische overwegingen van de 
onderzoeken uit dit proefschrift. Sterke punten van deze onderzoeken zijn de grote aantallen 
van patiënten en een representatieve groep uit de populatie. Zwakke punten zijn dat in het 
retrospectieve dossieronderzoek de gewenste plaats van overlijden niet bekend was en dat 
in het longitudinale vragenlijstenonderzoek vooral patiënten uit een academisch centrum 
deel hadden genomen. Daarna beschrijft de algemene discussie de hoofdbevindingen van 
ieder hoofdstuk in relatie tot de bekende literatuur en belicht het de behandeling, plaats van 
overlijden en beoogde en behaalde behandeldoelen van patiënten met uitgezaaide longkanker, 
tezamen met het perspectief van de artsen en nabestaanden over de behandeldoelen en de 
tevredenheid met de keuze van behandelen. In het laatste deel van het hoofdstuk worden 
enkele aanbevelingen voor de praktijk en toekomstig onderzoek beschreven. Deze bevatten 
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de noodzaak van palliatieve zorg in de laatste levensfase, recenter onderzoek naar het 
percentage patiënten dat behandeld wordt voor uitgezaaide longkanker en de aanbeveling 
voor meer onderzoek naar de reden en tevredenheid van het niet behandelen van uitgezaaide 
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Natuurlijk was ik de afgelopen jaren niet zo goed doorgekomen zonder mijn collega’s van 3F 
(lees als tree F). Samen zwoegen, koffie drinken, taart eten, lunchen, borrelen en feestjes, 
ik kan met recht zeggen dat ik elke dag van jullie genoot. Ik werd zo warm ontvangen door 
Cathelijne, Onno, Anna, Joanne en Anna-Larissa wat echt elke dag leuk maakte. Fietstochtjes 
met Joanne, passen op de poes van Anna en ik heb zelfs nog weken in jouw huis mogen 
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heerlijk mochten klagen op onze kamer. Niet veel later werd onze groep groter met Josien, die 
nog meer kan sporten dan ik, maar bovenal heel gezellig is en goed kan koken. Je kon mij niet 
blijer maken door jou als kamergenoot te hebben! Liza sloot bij ons aan met het enige nadeel 
dat jij het altijd warm hebt; ook in de winter moest het raam open waardoor Josien en ik met 
een sjaal om achter ons bureau zaten. Lies, je bent zo slim en oprecht, ik zal je missen als jullie 
in de States zijn. Om 3F nog gezelliger te maken dan het al was, werd Eveline aangenomen. 
Een warm persoon die altijd klaar staat voor een praatje en een borrel. Eef ik heb het altijd zo 
gezellig met je gehad op en buiten het werk, bedankt daarvoor! Verder wil ik Jelco, Samara, 
Natalia, Nicole, Chermaine, Jeroen, Jessie, Marieke en Azar bedanken voor het compleet 
maken van onze mooie afdeling. Heerlijk om met jullie tijdens de lunch te gaan hardlopen 
en vrijdag mee te borrelen. Door jullie is mijn PhD geweldig leuk en onvergetelijk geworden!
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Ook al was ik hier niet fysiek aanwezig, naast mijn collega’s op 3F had ik ook collega’s bij 
de Dode Hoek in het VU gebouw. Onze maandelijkse bijeenkomsten van de Junior Club 
waren fijn om elkaar even te spreken over goeie en slechte dingen uit onze onderzoeken en 
een mogelijkheid om elkaars papers te reviewen. Vina, Kirsten, Ian, Maud, Femmy, Hanna, 
Maureen, en Nicole, bedankt voor jullie hulp en steun bij eigenlijk nog best wel veel papers 
van mij. Verder herinneren jullie mij vooral aan koffie met taart en congressen waar je lekker 
kon eten en drinken ;). Wat hebben we daar gelachen! 
Naast de hulp en gezelligheid die ik hierboven benoem, ben ik heel blij dat jij zo’n goeie 
vriendin van mij bent geworden Kirsten. We hebben elkaar leren kennen bij de EpidM 
cursus in Maastricht en vanaf daar werd het alleen maar beter. Ik heb genoten van onze 
concertbezoeken, wijntjes, theetjes en etentjes. En nog steeds zien we elkaar vaak en het 
is altijd even fijn. De dynamiek gaat zelfs wat veranderen met het feit dat we beide (bijna) 
moeder zijn. Ik ga er zeker voor zorgen dat woensdag ook mijn vrije dag wordt, zet de wijn 
maar koud (en reserveer het KDV)!
Ook wil ik jou speciaal bedanken Hanna, voor al je hulp aan mijn stukken en het onderzoek 
wat we samen hebben gedaan. Wat een mooi en bijzonder persoon ben jij zeg, zo eerlijk en 
lief. Ik vond het heel erg fijn om samen met jou te werken. Gelukkig spreek ik jou ook nog 
steeds en hebben wij allebei een mooie en spannende tijd voor de boeg.
Niet per se mede-collega’s maar wel mede epidemiologie master studenten Anja, Tessa en 
Frank. Anja, wat ben jij toch enthousiast, gedreven, sportief en volhardend. Bedankt voor je 
statistische hulp, de koffietjes, schaatsritjes en etentjes. Tessa, met je uitstraling, charisma, 
intelligentie en humor was ik op de middelbare school vast bang voor je geweest, maar 
gelukkig is dat niet het geval! Bedankt voor je luisterend oor, hulp en steun bij de master en 
m’n promotieonderzoek. Frank, de meest muzikale, meelevende en geïnteresseerde man 
die ik ken. Ik ben blij dat ik jou heb leren kennen en dat we nu af en toe samen op de piano 
mogen spelen.
Grote dank en alle lof voor Karin, Bianca, Nienke, Warda en Jacqueline. Bedankt voor de 
hulp bij het includeren van de patiënten, mij op de hoogte houden van de behandelplannen 
en de fysieke en emotionele status van de patiënten. Jullie zijn fantastisch en werkelijk waar, 
onmisbaar.
Ella en Nynke, mijn geweldige paranimfen. Nynke, wij hebben elkaar leren kennen bij de 
Ronde Tafel in Emmeloord. Jij als huisarts en ik als promovenda hadden direct een klik op 
werkgebied. Maar later bleek dat we het daarnaast ook heel goed samen konden vinden met 
onze gedeelde interesses. Hardlopen, bakken, filmavondjes met wijn en kaas, we hadden elke 
week wel iets op de planning. Ik miste je ook erg toen ik naar Amsterdam verhuisde, maar 
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gelukkig zien we elkaar nog regelmatig. Ik ben erg blij dat je op deze dag naast mij staat, met 
die prachtige mooie jurk, hé Lex ;). Je bent lief, geïnteresseerd, oprecht en lekker nuchter. Dat 
laatste heb ik soms echt wel een beetje van je nodig, als ik me weer ergens druk om maak. Ik 
hoop dat we nog velen jaren goeie vriendinnen zullen blijven en dat we snel met Lex, Koen 
en Tijs op wintersport mogen gaan. 
Ella, mijn grote voorbeeld, rots in de branding en lieve vriendin. Wij hebben elkaar leren 
kennen bij het VUmc. Jij als coördinator van het stafsecretariaat en ik als één van de vele 
promovendi die haar administratie weer niet op orde had toen ze bij het VUmc kwam werken. 
Als snel kwamen we samen in de redactie van het personeelsblad van de afdeling Longziekten. 
Dan gingen we wel eens met z’n allen uit eten en we raakten steeds vaker samen aan de 
praat. Het klikte gewoon goed denk ik :). Meer avondjes volgden waarbij de wijn en kaasjes 
altijd van perfecte kwaliteit zijn. In april 2020 liep mijn contract af en ging jij met pensioen. 
Het lijkt mij niets mooiers om de jaren VUmc samen met jou af te sluiten. Je begrijpt het doel 
van mijn onderzoek en de ernst in deze patiëntenpopulatie als geen ander. Jouw gevoel voor 
taal heeft dit proefschrift wel degelijk verbeterd en als een van de weinige mensen heb jij (en 
Donné deels) het helemaal gelezen. Ik tref het maar Ella, mijn lieve vriendin, om jou naast mij 
te hebben tijdens de verdediging en deze mooie dag. Ik zou je nergens anders willen hebben 
dan aan mijn zijde. Donné, Anna en Elza, fijn dat ik jullie heb leren kennen!
Lieve Anny, Irma en Noortje. Waar was het secretariaat zonder jullie? Nou wacht even, waar 
was de hele afdeling Longziekten zonder jullie? Zonder jullie was er niemand die de kar trok 
en was het één grote chaos geworden. Jullie zijn fantastisch en als ik aan mijn jaren in het 
VUmc denk, denk ik aan jullie. Altijd in voor een praatje, lekkere taartjes bij de koffie, oprecht 
geïnteresseerd en zelfs nog een keer heerlijk met z’n allen gegeten bij mij thuis. Bedankt 
voor al jullie hulp!
Lieve Theo. Als iemand mij met hart en ziel heeft bijgestaan in mijn promotieonderzoek ben 
jij het wel. Vanaf het begin af aan hebben we elke week samen hardgelopen (zelfs de halve 
marathon van Amstelveen). Even m’n hoofd leegmaken, even kletsen over werk maar vooral 
over alle andere dingen in ons leven. Zelfs na mijn verhuizing naar Alkmaar zijn we elkaar 
blijven zien en rennen, wandelen of drinken we koffie samen. Ik hoop dat ik gelijk heb als ik 
zeg dat wel elkaar niet snel uit het oog zullen verliezen. Ik jou in ieder geval niet.
Rob, je bent me er een. Zo attent en behulpzaam. We hebben elkaar met de PhD training 
leren kennen en ik hoop dat we elkaar zullen blijven zien.
Lieve (tante) Julia, je bent met recht mijn gekste en grappigste vriendin. Mede-promovenda, 
mede-levensgenieter, goede kok en altijd up to date met de laatste mode. Ik heb je leren 
kennen op een kerstborrel van Jong Amsterdam UMC (zonnebrand bruin!) en sindsdien waren 
we onafscheidelijk. Wat mis ik de feestjes met jou! Gelukkig borrelen en eten we thuis vrolijk 
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verder. Het ping-pong feest met jullie Ires en Tjarda gaat voor mij de boeken in als laatste Jong 
Amsterdam UMC feestje. Bedankt voor alle gezelligheid dames! En wie kon die feestjes beter 
organiseren dan jij, Thomas. Ook met jou heb ik veel geborreld en theetjes gedronken, maar 
ook geboulderd en we waren zelfs naar La Roux. Je bent zo’n ambitieus, warm en grappig 
persoon, ik ben blij met jou als vriend!
Als we het hebben over de meeste koffietjes samen drinken sta jij met stip op één Ramon. Ik 
heb gegokt dat we samen meer koffie dan biertjes hebben gedronken, op de retreats, borrels, 
bij de CCA labdrinks en in de stad, maar correct me if I’m wrong. Ik heb het altijd erg gezellig 
met je en ben blij dat we de koffietjes nu naar het AVL hebben verplaatst.
Lieve Viviënne, dankzij onze promotieonderzoeken hebben wij elkaar leren kennen op een 
congres in Eindhoven. Beide met een Garmin sporthorloge om was er meteen een klik. Ik 
kan altijd goed met je sparren over werk, maar daarbuiten vind ik je een heel mooi en fijn 
persoon om mee om te gaan. Bedankt voor de mooie fietsritjes, etentjes en gezelligheid!
Lieve Hester, wij hebben elkaar leren kennen op de OOA retreat, waar iedereen dacht dat we 
zusjes waren. We delen niet alleen veel gelijkenissen in uiterlijk, opleiding en werk (nu zelfs 
allebei op het NKI), maar ook in onze sportiviteit. En als ik het mag wensen, hoop ik ook in 
jouw gedrevenheid, want dat is een van de dingen die ik zo mooi aan jou vind. Bedankt voor 
alle goeie gesprekken en ik wens je heel veel succes met je verdere carrière, het is je gegund!
Dear Dan and Philippa, our activity and beers partners in crime! No activity can be 
accomplished without a beer after. I enjoyed all the running, cycling, rock climbing, mushroom 
picking, boating, games, dinners and drinks with you guys. Special thanks to you Pips, for 
reading this entire thesis (!) to improve the English language. You are such a warm, kind and 
sweet person, I am blessed to have you in my life.
Dank Frank. Sidney, Dakota en Meadow.
Ik heb meerdere cursussen richting carrière en persoonlijke ontwikkeling gevolgd en deze 
vraag kwam hier vaak naar voren: wat is voor jou het allerbelangrijkste in je leven? Voor mij 
is dat familie. Lieve familie, jullie zijn mij zoveel waard. Bij jullie kan ik mezelf zijn, hebben 
we het gezellig, doen we leuke dingen en kletsen we onder andere ook over mijn onderzoek. 
Wim en Joke, jullie zijn slim en betrokken, altijd geïnteresseerd en ik ambieer een levensstijl 
zoals die van jullie; ambitieus, sportief en sociaal actief. Fenna, Fiene, Didde, Ole en Jibbe, bij 
jullie is het altijd gezellig. Wijntjes met jou Fen, en bios, logeerpartijtjes, schilderen, bakken 
en wiskunde sommen maken met de kids. Ik geniet altijd van jullie. Giel, Celine, Faye, Gieltje, 
Benn en Youp, bij jullie ben ik kind aan huis. Giel’s uitstekende kookkunsten, oneindig veel 
avondjes kletsen en wijn drinken met jou Celine, de leuke dagjes Amsterdam met Faye, karten 
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met Gieltje en oppassen op de allerkleinste, dit zijn de dingen die mij zo blij maken. Celine, 
jij bent een van de weinige mensen die echt alles van mij weet. Je bent zo open, eerlijk en 
lief. Als een van ons ergens mee zit hangen we uren aan de telefoon om ons hart te luchten. 
Jij bent echt de eerste persoon die ik bel als er iets aan de hand is. Ik weet dat je er altijd 
voor me zult zijn, mentaal maar ook fysiek, met boodschapjes en bezoekjes als ik ziek ben. Ik 
hoop dat ik half zoveel terug doe voor jou als jij voor mij. Je bent een ongelofelijk bijzonder 
mens. Lieve Auke, Yummee en Emma, wat zijn jullie geïnteresseerd, oprecht en wat een 
mooi gezin hebben jullie.
Oege, Tineke, Franke, Lidia, Mitt, Site, Elze en Linn. De sportieve en gezellige schoonfamilie! 
Ze zeggen altijd dat je die er gratis bijkrijgt als je voor je partner kiest, maar ik heb bijna voor 
Wessel gekozen om jullie te mogen leren kennen. ;) Oege en Tineke, bedankt voor het lieve 
warme nest waar we altijd naartoe mogen komen. Ik voel me heel erg thuis bij jullie. De koffie 
staat altijd klaar, de koelkast gevuld en de bedjes opgemaakt. Samen wandelen, wielrennen 
en schaatsen, meer kan ik niet wensen!
Lieve oma. Dit jaar wordt u 90 jaar en promoveren is iets wat u niet kende. Het bleef lastig 
met tentamens die ik moest maken voor m’n tweede master en de functie PhD-student. 
Studeerde ik nou wel of niet? U wist het niet zo goed, maar trots en blij bent u altijd wel. Ik 
geniet van onze wekelijkse etentjes samen en onze 3-maandelijkse kapper date. Ik hoop dat 
ik u nog lang bij mij mag houden want ik ben echt heel erg gek op u.
Lieve mama. Ik heb woorden tekort om jou te omschrijven, maar trots is er zeker een van. 
Wat zul je trots zijn dat dit boek hier voor je ligt. Trots op de twee bachelors en twee masters 
die ik gehaald heb en iedereen in jouw dorp weet nu ook dat ik bijna doctor ben. Ik vind het 
zo knap van je dat jij trots kunt zijn voor twee, want dat is wel een van de gaten die jij moet 
vullen. En wat doe je dat goed. Jouw trots motiveert mij om door te gaan en zorgt ervoor dat 
ik nu ben wie ik ben. Jouw liefde voor mij (voor ons) is onvoorwaardelijk en ik weet dat je er 
altijd voor me zult zijn. Bedankt voor je liefde, je steun, je aanwezigheid bij alle uitreikingen 
en presentaties en bedankt dat ik jou mijn moeder mag noemen.
De laatste woorden van dit proefschrift zijn voor twee heel bijzondere mensen in mijn leven. 
Lieve Wessel, we hebben elkaar leren kennen op de racefiets en het heeft even geduurd 
totdat deze fietsritjes iets meer werden dan enkel fit blijven in de buitenlucht. De tripjes naar 
Zwitserland en Limburg om te fietsen en naar Noorwegen om te skiën lieten wel zien dat wij 
het samen heel erg leuk konden hebben. En daarna zijn er nog veel mooie momenten gevolgd. 
Samen sporten, reizen, oneindig veel kletsen, koken en lekker eten en drinken, je bent echt 
mijn beste maatje om dit allemaal mee te doen. En dan zijn we door het thuiswerken ook 
nog eens collega’s geworden, wat een feest! Elke dag samen koffie drinken, lunchen en 
wandelingetjes maken. Tijdens mijn promotieonderzoek en mijn baan die volgde ben je altijd 
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een luisterend oor geweest. Je steunt me, bent kritisch op de dingen waar ik tegenaan loop 
en denkt altijd mee. Dank voor je steun en je liefde hierin.
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